CURRICULUM VITAE

Daniel K. Nomura, Ph.D.
Professor of Chemical Biology and Molecular Therapeutics
University of California, Berkeley
Departments of Chemistry and Molecular and Cell Biology
Molecular Therapeutics Initiative
Innovative Genomics Institute
2151 Berkeley Way, Rm 312G
Berkeley, CA 94720
DNomura@berkeley.edu
Office: 510-643-7258
Cell: 510-798-9647
Nomuraresearchgroup.com

Education

2008-2011	Postdoctoral Fellow in Chemical Physiology Scripps Research (Advisor: Benjamin F. Cravatt)
2004-2008	Ph.D. in Molecular Toxicology University of California, Berkeley (Advisor: John E. Casida)
1999-2003	B.A. in Molecular and Cell Biology University of California, Berkeley (Advisor: John E. Casida)

Positions

2026-current	Distinguished Visiting Professor, Kyoto University
2024-current	Co-Director, Molecular Therapeutics Initiative, UC Berkeley
2023-current	Professor (with tenure) University of California, Berkeley Department of Chemistry Department of Molecular and Cell Biology, Division of Molecular Therapeutics
2019-2023	Professor (with tenure) University of California, Berkeley Departments of Chemistry, Molecular and Cell Biology, and Nutritional Sciences and Toxicology
2019-current	Adjunct Professor University of California, San Francisco; Department of Pharmaceutical Chemistry
2017-current	Director, Novartis-Berkeley Translational Chemical Biology Institute (NB-TCBI)
2016-2019	Associate Adjunct Professor University of California, San Francisco Department of Pharmaceutical Chemistry
2015-2019	Associate Professor (with tenure) University of California, Berkeley Departments of Chemistry, Molecular and Cell Biology, and Nutritional Sciences and Toxicology
2011-2015	Assistant Professor University of California, Berkeley Department of Nutritional Sciences and Toxicology
2008-2011	Postdoctoral Fellow Scripps Research, La Jolla, CA; Department of Chemical Physiology Advisor: Professor Benjamin F. Cravatt
2004-2008	Graduate Researcher
2003-2004	Research Associate
2000-2003	Undergraduate Research Assistant University of California, Berkeley Department of Nutritional Sciences and Toxicology Advisor: Professor John E. Casida

Daniel K. Nomura Biography

Dan Nomura is Professor of Chemical Biology and Molecular Therapeutics in the Departments of Chemistry and Molecular and Cell Biology at the University of California, Berkeley, where he is Co-Director of the Molecular Therapeutics Initiative and an Investigator at the Innovative Genomics Institute. He is also Distinguished Visiting Professor at Kyoto University's Institute for Integrated Cell-Material Sciences (iCeMS) and Adjunct Professor in the Department of Pharmaceutical Chemistry at the University of California, San Francisco. Nomura's research integrates chemical biology, chemoproteomics, and medicinal chemistry to develop innovative therapeutic strategies for previously undruggable disease targets. Since 2017, he has directed the Novartis-Berkeley Translational Chemical Biology Institute, a collaborative research program focused on discovering next-generation medicines by leveraging chemoproteomic technologies. He has co-founded multiple biotechnology companies translating these discoveries into therapeutics, including Frontier Medicines, which applies chemoproteomics and machine learning to discover medicines for challenging targets, and Zenith Therapeutics, which is developing induced proximity-based therapeutics for undruggable proteins. He also serves on the Scientific Advisory Boards of Frontier Medicines, Zenith Therapeutics, Apertor Pharma, Photys Therapeutics, Endura Therapeutics, Axiom Therapeutics, Deciphera Pharmaceuticals, Serinus Biosciences, and Ten30 Biosciences. In addition, he serves as an Investment Advisory Partner at Andreessen Horowitz (a16z) Bio + Health, an Investment Advisory Board member at Droia Ventures, and an iPartner at The Column Group. Nomura serves on the Scientific Advisory Committee of the American Association for Cancer Research (AACR) and on the Scientific Advisory Board of The Mark Foundation for Cancer Research. In 2025, he became Editor-in-Chief of *Molecular Cancer Therapeutics*. Nomura received his B.A. in Molecular and Cell Biology and Ph.D. in Molecular Toxicology from UC Berkeley under the mentorship of John Casida before completing postdoctoral training with Benjamin F. Cravatt at Scripps Research. He joined the UC Berkeley faculty in 2011. His contributions to chemical biology and translational therapeutics have been recognized through numerous honors, including the National Cancer Institute Outstanding Investigator Award, the Searle Scholar Award, and The Mark Foundation for Cancer Research ASPIRE Award. His laboratory pioneers chemoproteomic technologies and induced proximity-based therapeutic platforms that redefine druggability, enabling the discovery of transformative medicines against previously inaccessible disease targets.

Reimagining Drug Discovery Through Chemoproteomics and Induced Proximity

The Nomura Research Group seeks to redefine the boundaries of drug discovery by developing chemical technologies that enable therapeutic intervention against proteins and pathways previously considered undruggable. Our overarching goal is to discover transformative medicines by identifying new ligandable sites within the proteome and harnessing these discoveries to create entirely new therapeutic modalities. Traditional small-molecule drug discovery has focused on the limited fraction of proteins possessing well-defined ligand-binding pockets. In contrast, we leverage chemoproteomic technologies to systematically map functional and pharmacologically accessible hotspots across the proteome, dramatically expanding the universe of proteins that can be therapeutically targeted. Our research is organized around three complementary directions. First, we develop next-generation chemoproteomic platforms to discover functional ligandable hotspots throughout the proteome and rapidly identify covalent small-molecule ligands against challenging disease targets. These technologies provide new therapeutic entry points into proteins previously considered inaccessible to pharmacological intervention. Second, we engineer chemoproteomic approaches that extend targeted protein degradation beyond conventional paradigms by discovering new ligands, new recruitment mechanisms, and new strategies for selectively eliminating disease-causing proteins. These efforts broaden the range of proteins that can be therapeutically degraded and expand the biological processes amenable to targeted degradation. Third, beyond protein degradation, we develop entirely new induced proximity-based therapeutic strategies that reprogram protein function, transcription, signaling, and cell fate. By combining chemoproteomic ligand discovery with induced proximity engineering, we aim to create next-generation therapeutic modalities capable of regulating biology in ways that were previously impossible with conventional drugs. Collectively, our work integrates chemoproteomics, chemical biology, medicinal chemistry, and systems biology to establish a comprehensive framework for discovering transformative therapeutics against the most challenging targets in human disease.

Theme 1: Chemoproteomics-Enabled Covalent Ligand Discovery Against the Undruggable Proteome
The central challenge in modern drug discovery is that the vast majority of disease-driving proteins remain undruggable by conventional small molecules. Our laboratory develops chemoproteomic technologies to systematically uncover cryptic ligandable hotspots throughout the human proteome and transform these previously inaccessible proteins into tractable therapeutic targets. Using quantitative chemoproteomics, we have mapped more than 100,000 ligandable sites across over 16,000 human proteins, including ligandable hotspots within the majority of genetically linked cancer drivers. These maps provide a foundation for discovering covalent ligands against transcription factors, intrinsically disordered proteins, signaling proteins, and other historically undruggable targets. We integrate large-scale covalent ligand screening with chemoproteomic target deconvolution to rapidly identify functional covalent ligands, define their proteome-wide selectivity, elucidate mechanisms of action, and optimize therapeutic leads. By combining synthetic chemistry, chemical biology, proteomics, and disease biology, our goal is to establish a generalizable platform for developing first-in-class therapeutics against the undruggable proteome.

Theme 2: Expanding the Scope of Targeted Protein Degradation
Targeted protein degradation (TPD) has transformed the way we think about drug discovery by enabling the selective elimination of disease-causing proteins rather than simply inhibiting their activity. Our laboratory develops next-generation TPD technologies that dramatically expand both the range of degradable proteins and the cellular machinery that can be harnessed for degradation. A major limitation of current degradation strategies is the scarcity of ligands for both undruggable targets and E3 ubiquitin ligases. We address both challenges through chemoproteomic discovery platforms that identify covalent ligands against disease-associated proteins as well as novel recruiters of E3 ligases and other components of the cellular protein quality control machinery. These discoveries enable the creation of innovative degrader architectures that extend beyond conventional PROTACs. In parallel, we are developing systematic approaches for discovering and engineering molecular glue degraders. Rather than relying on serendipitous discoveries, we combine chemoproteomics with phenotypic screening and proteome-wide target deconvolution to identify small molecules that induce productive protein-protein interactions and rapidly define the molecular basis of their activity. Together, these efforts establish new principles for programmable protein degradation across the proteome.

Theme 3: Discovering Next-Generation Induced Proximity Therapeutics
Induced proximity represents a fundamentally new paradigm for drug discovery. Rather than simply inhibiting or degrading proteins, induced proximity therapeutics create entirely new protein interactions that reprogram cellular function through gain-of-function mechanisms. Our laboratory is pioneering new classes of induced proximity therapeutics that extend far beyond targeted protein degradation. By combining chemoproteomics with heterobifunctional molecules and molecular glues, we develop technologies that recruit diverse cellular proteins and enzymes to rewire biology in programmable ways. These platforms enable transcriptional repression and activation, protein stabilization, signal rewiring, epigenetic reprogramming, and other emerging therapeutic modalities. A major focus of our research is the development of programmable transcriptional therapeutics that selectively reprogram gene expression through targeted recruitment of chromatin regulators and transcriptional machinery. More broadly, we seek to establish a comprehensive toolkit of induced proximity strategies capable of controlling virtually any protein function, ultimately creating entirely new therapeutic modalities for diseases that remain beyond the reach of conventional pharmacology.

Awards and Fellowships

2025	Miller Research Professorship Award
2024	Bakar Fellows Spark Award
2022	National Cancer Institute Outstanding Investigator Award
2019	Mark Foundation for Cancer Research ASPIRE award
2015	ACS Research Scholar Award
2015	DOD Breakthroughs Award Recipient
2013	Eicosanoid Research Foundation Young Investigator Award
2013	Hellman Fellows Awardee
2012	Searle Scholar Award
2010	NIH Pathway to Independence (PI) Award (K99/R00)
2009	American Cancer Society Postdoctoral Fellowship

Affiliations

2026-current	Distinguished Visiting Professor, Kyoto University, Institute for Integrated Cell-Material Sciences (iCeMS)
2026-current	Scientific Advisory Board of Serinus Biosciences
2025-current	Scientific Advisory Board of Endura Therapeutics
2025-current	Scientific Advisory Committee member of American Association for Cancer Research (AACR)
2025-current	Scientific Advisory Board member for Axiom Therapeutics
2025-current	Editor-in-Chief for Molecular Cancer Therapeutics
2024-current	Editorial Advisory Board member for ACS Central Science
2024-current	Scientific Advisory Board member for Ten30 Biosciences
2024-current	Co-Founder and Scientific Adviser for Lobos Therapeutics
2024-current	Co-Founder and Scientific Adviser for Zenith
2024-current	Co-Director of the Molecular Therapeutics Initiative at UC Berkeley
2024-current	Scientific Advisory Board member of Deciphera Pharmaceuticals
2023-current	iPartner at The Column Group
2023-2024	Scientific Advisory Board member of MD Anderson Cancer Center
2023-current	Investment Advisory Partner at a16z
2023-2023	Scientific Advisory Board member of Proravel Therapeutics
2023-2025	Scientific Advisory Board member of Oerth Bio
2022-current	Droia Ventures Investment Advisory Board member
2022-current	Faculty in the Department of Molecular and Cell Biology, Molecular Therapeutics Division (UC Berkeley)
2022-2023	Director of the BMS-Berkeley Center for Chemical Biology and Therapeutics
2022-2024	Director of the Amgen-Berkeley Chemoproteomics Center of Excellence
2022-current	Scientific Advisory Board member of Apertor Pharmaceuticals
2022-2025	American Association for Cancer Research (AACR) Chemistry in Cancer Research Working Group Steering Committee member
2022-2025	Founder, Chair of the Scientific Advisory Board, and Chair of the Board of Directors for Vicinitas Therapeutics ($65 MM Series A funding)
2022-current	Associate Editor, Chemical Research in Toxicology
2021-current	Scientific Advisory Board member of Photys Therapeutics
2021-2022	Consultant for Droia Ventures
2021-current	Editorial Board Member of Cell Chemical Biology
2021-current	Scientific Advisory Committee Member, Mark Foundation for Cancer Research
2020-current	Scientific Advisory Board for the Undruggables, Kisaco Research
2019-current	Investigator, Innovative Genomics Institute
2018-2021	Associate Editor of Cell Chemical Biology
2018-current	Editor of Current Protocols in Chemical Biology
2018-current	Co-Founder, Chair of the Scientific Advisory Board, and Consultant for Frontier Medicines ($67 MM Series A funding, $50 MM Abbvie partnership, $89 MM Series B funding; $80 MM Series C funding)
2018-current	Editorial Advisory Board for Chemical Research in Toxicology
2017-current	Director, Novartis-Berkeley Translational Chemical Biology Institute
2016-current	Member, UCSF Helen Diller Family Comprehensive Cancer Center
2016-current	Member, UCSF Breast Oncology Program
2016-2022	Faculty in the Department of Molecular and Cell Biology, Biochemistry, Biophysics, and Structural Biology Division (UC Berkeley)
2016-current	Adjunct Professor at UCSF, Department of Pharmaceutical Chemistry
2015-current	Faculty in the Department of Chemistry (UC Berkeley)
2015-2018	Adviser for 3-V Biosciences
2012-2019	Adviser for Abide Therapeutics (Acquired by Lundbeck Pharma in 2019)
2012-current	Member of the Center for Emerging and Neglected Diseases (UC Berkeley)
2012-2020	Endocrinology Graduate Group (UC Berkeley)
2011-2022	Program in Metabolic Biology (UC Berkeley)
2011-current	Member of Chemical Biology Graduate Group (UC Berkeley)

2011-2024	Member of Molecular Toxicology Graduate Group (UC Berkeley)
2011-2022	Member of Molecular and Biochemical Nutrition Graduate Group (UC Berkeley)
2011-2022	Faculty in the Department of Nutritional Sciences and Toxicology (UC Berkeley)

Professional Associations

2004-current	American Chemical Society
2021-current	American Association for Cancer Research member
2004-2008	Society of Toxicology

Academic Services

2026-current	Director of the Biomarin-MTI Collaborative
2024-current	Co-Director of the Molecular Therapeutics Initiative at UC Berkeley
2022-2024	Director of the Amgen-Berkeley Chemoproteomics Center of Excellence
2022-2023	Director of the BMS-Berkeley Center for Chemical Biology and Therapeutics
2021	Member, Faculty selection committee for hiring in chemistry for the Department of Chemistry
2020-current	Molecular and Cell Biology graduate admissions committee member
2018-2019	NST space committee
2018	Cal Day NST Speaker
2018-2020	Miller Fellow Advisory Committee for the Department of Chemistry
2017-current	Director, Novartis-Berkeley Translational Chemical Biology Institute
2017-2021	Member, Animal Care and Use Committee
2017-2019	Member, College of Natural Resources Executive Committee
2017	Cal Day NST Speaker
2016-2017	Member, Faculty selection committee for hiring in cancer biology for the Molecular and Cell Biology department
2016-2017	Member, Faculty selection committee for hiring the next chair for the Nutritional Sciences and Toxicology department
2016-2017	Faculty adviser for Chemistry-Chemical Biology students
2016-2022	Member, Executive/Long Range Planning committee for Nutritional Sciences and Toxicology
2016-2017	Member, working group to advise on academic realignment as it pertains to the College of Natural Resources and the L&S Biological Sciences Division
2016-2021	Member, Committee for Laboratory and Environmental Biosafety
2014-2024	Chair and Head Graduate Adviser, Molecular Toxicology Graduate Program
2014-2018	Member, CNR Student Faculty Relations Committee
2014	Member, Molecular and Cell Biology Cancer Faculty Search Committee
2014	Speaker for CalSO Faculty Showcase
2013-2017	Member, Metabolic Biology Graduate Affairs Committee
2012-current	Regents' and Chancellors' Scholarship Faculty Mentor
2012	Member, Faculty Selection committee for the Nutritional Sciences and Toxicology Department
2012-2017	Member, Seminar Speaker Selection Committee
2011-2018	Member, Undergraduate Affairs Committee for the Nutritional Sciences and Toxicology Department
2011-2024	Member, Molecular Toxicology Graduate Affairs Committee

Professional Services

2026	Chair of the AACR-The Mark Foundation for Cancer Research Chemistry in Cancer Research Scientific Review Committee
2025-current	AACR Scientific Advisory Committee member
2025-current	Editor-in-Chief, Molecular Cancer Therapeutics
2024-current	Editorial Advisory Board member for ACS Central Science
2024-current	Co-Director of the Molecular Therapeutics Initiative at UC Berkeley

2023-2024	Co-Chair for AACR Annual Meeting 2024 Program Committee
2023	Chair for the Bioorganic Chemistry Gordon Research Conference
2023-2024	Scientific Advisory Board member of MD Anderson Cancer Center
2022-2026	Standing Member for NIH Chemical Biology and Probes Study Section (CBP)
2022	Standing Member for NIH Synthetic and Biological Chemistry A Study Section (SBCA)
2022-current	Associate Editor for Chemical Research in Toxicology
2022	Astrazeneca, External Scientific Advisory Panel Member
2022	Vice Chair for Bioorganic Chemistry Gordon Research Conference
2021-2022	External Scientific Consultant for the National Cancer Institute Fusion Oncoproteins in Childhood Cancers (FuSOnC2) Program
2021-current	Scientific Advisory Committee Member, Mark Foundation for Cancer Research
2021-current	Editorial Board Member of Cell Chemical Biology
2018-2021	Editor of Cell Chemical Biology
2018-current	Editor of Current Protocols in Chemical Biology
2018-current	Editorial Advisory Board for Chemical Research in Toxicology
2018	Discussion Leader at 2018 Bioorganic Chemistry Gordon Research Conference, Andover, New Hampshire.
2018	Study section ad hoc member for Enabling Bioanalytical and Imaging Technologies (EBIT) study section
2018	Chair and organizer of EMBO meeting “Enzymes, biocatalysis and chemical biology: The new frontiers” Pavia, Italy.
2018	Chair and organizer of “Chemoproteomics and Metabolomics” session at 2018 ASBMB Experimental Biology meeting, San Diego
2017-2019	Study section ad hoc member for Cancer Drug Development & Therapeutics (CDDT) study section
2016	Study section ad hoc member for Recurring Special Emphasis Panel NIH ZRG1 BMCT-C(01) Molecular Targets and Cancer Intervention study section
2016	Study section member for Special Emphasis Panel NIH ZRG1 BSTU 50
2015	Editor for “Omics” Issue in Current Opinions in Chemical Biology
2011	Editor Special Issue for Biochimica Biophysica Acta (Lipids in Cancer)

Reviewer for: Cell, Molecular Cell, Cell Chemical Biology, Cell Metabolism, Cell Reports, Chem, Chemical Neurosciences, Chemical Reviews, Nature, Molecular Cancer Therapeutics, Nature Chemical Biology, Nature Cell Biology, Chemical Sciences, PNAS, Biochimica et Biophysica Acta, Journal of the American Chemical Society, Angewandte Chemie, Nature Structural and Molecular Biology, Journal of Lipid Research, Journal of Clinical Investigation, Cancer and Metabolism, Molecular and Cellular Proteomics, ACS Chemical Biology, ACS Central Science, Journal of Biological Chemistry, eLife, Nature Chemistry

Teaching

Fall 2026	UC Berkeley Instructor for Therapeutic Discovery and Development (MCB120)
Fall 2025	UC Berkeley Instructor for MCB Special Seminar (MCB290)
Fall 2025	UC Berkeley Instructor for Therapeutic Discovery and Development (MCB120)
Fall 2024	UC Berkeley Instructor for Therapeutic Discovery and Development (MCB120)
Fall 2024	UC Berkeley Instructor for Graduate Level Bioorganic Chemistry (Chem 295)
Fall 2023	UC Berkeley Instructor for Therapeutic Discovery and Development (MCB120)
Fall 2023	UC Berkeley Instructor for Research in Chemistry (Chem 96)
Fall 2022	UC Berkeley Instructor for Advanced Toxicology (NST110)
Fall 2022	UC Berkeley Instructor for Chemical Biology (Chem135)
Spring 2022	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Fall 2021	UC Berkeley Instructor for Freshman Seminar on: Chemical Biology as an Engine for Drug Discovery (Chem 24)
Fall 2021	UC Berkeley Instructor for
Spring 2021	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Spring 2021	UC Berkeley Instructor for Research in Toxicology (NST193)

Fall 2020	UC Berkeley Instructor for Advanced Toxicology (NST110)
Spring 2020	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Spring 2020	UC Berkeley Instructor for Research in Toxicology (NST193)
Spring 2020	UC Berkeley Instructor for Advanced Seminar in MCB (MCB290)
Fall 2019	UC Berkeley Instructor for Advanced Toxicology (NST110)
Fall 2018	UC Berkeley Instructor for Advanced Toxicology (NST110)
Spring 2018	UC Berkeley Instructor for Research in Toxicology (NST193)
Spring 2018	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Fall 2017	UC Berkeley Instructor for Advanced Toxicology (NST110)
Spring 2017	UC Berkeley Instructor for Research in Toxicology (NST193)
Spring 2017	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Fall 2016	UC Berkeley Instructor for Advanced Toxicology (NST110)
Spring 2016	UC Berkeley Instructor for Research in Toxicology (NST193)
Spring 2016	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Fall 2015	UC Berkeley Instructor for Advanced Toxicology (NST110)
Spring 2015	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Spring 2015	UC Berkeley Instructor for Research in Toxicology (NST193)
Fall 2014	UC Berkeley Instructor for Advanced Toxicology (NST110)
Spring 2014	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Fall 2013	UC Berkeley Instructor for Advanced Toxicology (NST110)
Spring 2013	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Spring 2012	UC Berkeley Instructor for Graduate Research Colloquium (NST292)
Spring 2012	UC Berkeley Instructor for Graduate Seminar (NST290): Chemical Approaches to Study Metabolism
Fall 2011	UC Berkeley Instructor for Undergraduate Special Seminar (NST190): "-Omic Approaches to Study Metabolism"
Spring 2007	UC Berkeley Lecturer for Molecular Toxicology (NST120)
Fall 2006	UC Berkeley Co-Instructor and Graduate Student Instructor for Advanced Toxicology (NST110)
Spring 2006	UC Berkeley Guest Lecturer for Pesticide Chemistry and Toxicology (ESPM148)
Spring 2006	UC Berkeley Lecturer for Molecular Toxicology (NST120)

Publications

1. Do Cong T, Shao Q, Ford B, Ladner C, **Nomura DK**. An insect E2-targeting covalent degradative handle for targeted protein degradation applications. In preparation
2. Tomlinson SJ, Johnson SL, Kroskrity AH, Hu Y, Deol KK, Zhang CY, Harris CA, **Nomura DK***, Olzmann JA* (2026) Induced ubiquitination drives ER protein degradation through a VCP-dependent pathway. *BioRxiv* doi: https://doi.org/10.1101/2025.11.28691080; *Journal of Cell Biology,* In press. (*co-corresponding author)
3. Nuttall TM, Modi A, Li K, Lau EA, Zhang A, Malik B, Guney T, Eksterowicz J, Notte GT, Maimone TJ, **Nomura DK** (2026) Stereoselective covalent inhibitor of the ovarian cancer-driving transcription factor PAX8. *BioRxiv*. doi: https://doi.org/10.64898/2026.08.15.745031.
4. Zammit CM, **Nomura DK** (2026) Covalent ligands that target the human papillomavirus E6 oncoprotein. *Chembiochem*, 27, e70590, doi:10.1002/cbic.70590. PMID 42985943
5. Stieger CE, Chen X, Kuismi CC, Dovala D, Fuller D, Frank AO, Woldegiorgis M, Bruce-Smythe M, Wu F, Pizzato N, McKenna J, Johannessen C, Fodor BD, Schirle M, **Nomura DK.** (2026) Targeted transcriptional repression by induced proximity. *ACS Central Science,* 12, 1008-1020. PMID 42500035
6. Modi A, Toriki ES, Stieger CE, Lau EA, Song C, Chew A, Tsao A, Nishikawa K, McKenna JM, **Nomura DK**. (2026) An optimized RNF126-targeting covalent handle for molecular glue degraders. *Bioorganic Medicinal Chemistry Letters*, doi: 10.1016/j.bmcl.2026.130743. PMID 42492625
7. Do Cong T, Chan H, Greene J, Sabaat S, Ludwig C, Abell NS, Albert ML, Kosuri S, **Nomura DK** (2026) Covalent modulators of immune-regulating transcription factors IRF8 and IRF5. *BioRxiv* doi: https://doi.org/10.1101/2025.08.03.668300.
8. King EA, Meyers M, **Nomura DK** (2026) Induced Proximity-Based Therapeutic Modalities. *Nature Reviews Drug Discovery*, 25, 175-203. PMID 41174297

9. Lin S, Berdan C, Sandy M, Lu X, Ramani V, **Nomura DK**, Chen X, Lee J, Goga A. (2026) Methionine metabolism and the NOP2 methyltransferase are essential for MYC-driven liver tumorigenesis. *BioRxiv*, doi: 10.64898/2026.01.28.702329. PMID 41659612
10. Illingworth ER, Sanchez SS, Rychlik KA, Kleensang A, Laird J, Lopez-Cecetaite GA, Rodriguez Steube MC, Mathur A, Sadhukhan P, Medina-Cleghorn DA, **Nomura DK**, Smith MT, Hoque MO, Sille FCM. (2026) Low-dose inorganic arsenic exposure reprograms macrophages differentiation and function toward tumor-promoting phenotypes. *Environmental Research*, 303, 124699. PMID 42105843
11. Chan MP, Advincula R, Achacoso P, Grossman EA, **Nomura DK**, Malynn BA, Ma A. (2025) A20 restriction of nitric oxide production restores macrophage bioenergetic balance. *BioRxiv*, doi: 10/1101/2025.10.26.684676. PMID 41279106
12. Duong TN, Pandji E, Shao Q,* **Nomura DK*.** (2025) Discovery of non-degradative covalent molecular glues for transcriptional reprogramming. *BioRxiv*, https://doi.org/10.64898/2025.12.12.694031. (*co-corresponding author)
13. Page ACS*, Orr LM, Meyers ML, Belcher BP, Coffey TG, Scholz SO, Cismoski S, **Nomura DK****, Toste FD. (2025) Development of second-generation acyl silane photoaffinity probes for cellular chemoproteomic profiling. *ACS Chemical Biology,* 20, 2601-2608. PMID 41076584 (*co-first authors; **co-corresponding authors)
14. Sturla DJ, Dai J, **Nomura DK**, Wang Y, Juarez-Moreno K, Tetko IV, Gupta K (2025) Introducing the inaugural early career board for Chemical Research in Toxicology. *Chem. Res. Toxicol.* 38, 1283. PMID 40820513
15. Williams J, Camarda R, Malkov S, Zimmerman LJ, Manning S, Aran D, Beardsley A, Van de Mark D, Nakagawa R, Chen Y, Berdan C, Louie SM, Mahieu C, Superville D, Winkler J, Willey E, Hutchins EJ, Gagnon JD, Avsaroglu SK, Shinoda K, Gruner M, Nishida H, Ansel KM, Werb Z, **Nomura DK**, Kajimura S, Butte AJ, Sanders ME, Liebler DC, Rugo HS, Krings G, Shepherd JA, Goga A (2025) Tumor cell-adipocyte gap junctions activate lipolysis and contribute to breast tumorigenesis. *Nature Communications*, 16, 7438. PMID 40835606
16. Rosen HT*, Li K*, Stieger CE, Li E, Currier B, Brittain SM, Garcia FJ, Beard DC, Jones MD, Haenni-Holzinger S, Dovala D, McKenna JM, Schirle M, Maimone TJ[#], **Nomura DK[#].** (2025) Sulfinyl aziridines as stereoselective covalent destabilizing degraders of the oncogenic transcription factor MYC. *Angewandte Chemie International Edition,* doi: 10.1002/anie.202508518. PMID 400999784 (*co-first authors; # co-corresponding authors)
17. Orr LM, Tomlinson SJ, Grupe HR, Lim M, Ho E, Yilmaz H, Zhou G, Chie-Leon B, Olzmann JA*, **Nomura DK***. (2025) DCAF16-based covalent degradative handles for the modular design of degraders. *ACS Central Science*, doi: 10.1021/acscentsci.5c00959. (*co-corresponding authors)
18. Zammit CM*, Nadel C*, Lin Y, Koirala S, Ahani E, Potts PR[#], **Nomura DK[#]**. (2025) Covalent destabilizing degrader of AR and AR-V7 in androgen-independent prostate cancer cells. *JACS*, 147, 20512-20524. PMID 40490871 (*co-first authors; # co-corresponding authors)
19. Skakuj K, Iglhaut M, Shao Q, Garcia F, Huang B-Y, Brittain S, Nesvizhskii A, Schirle M, **Nomura DK**, Toste FD. (2024) Light-activated reactivity of nitrones with amino acids and proteins. *Angewandte Chemie International Edition*, 64, e202415976. PMID 39509590
20. **Nomura DK**. (2025) A vision for the future of molecular cancer therapeutics. *Molecular Cancer Therapeutics*, 24, 663. PMID 40313095
21. Bajaj T, Mosavati B, Zhang LH, Parsa MS, Wang H, Kerek EM, Liang X, Tabatabaei Dakhili SA, Wehri E, Guo S, Desai RN, Orr LM, Mofrad MRK, Schaletzky J, Ussher JR, Deng X, Stanley R, Hubbard BP, **Nomura DK**, Murthy N. (2025) Identification of acrylamide-based covalent inhibitors of SARS-CoV-2 (SCoV-2) Nsp15 using high-throughput screening and machine learning. *RSC Advances*, 15, 10243-10256. PMID 40182494
22. Qiu Y*, Thomas VCJX*, Fantoni T, Chen R, Jiang X, He Z-T, Butcher TW, **Nomura DK****, Hartwig JF** (2024) Convergent synthesis and protein binding of vicinal difluorides by stereodivergent C-C bond formation. *Chem,* 10, 1-13. (*co-first authors; **co-corresponding authors)
23. Shao Q, Duong TN, Park I, Orr LM, **Nomura DK** (2024) Targeted protein localization by covalent 14-3-3 recruitment. *JACS*, 146, 24788-24799. PMID 39196545
24. Gowans FA*, Forte N*, Hatcher J, Huang OW, Wang Y, Altamirano Poblano BE, Wertz IE, **Nomura DK** (2024) Covalent degrader of the oncogenic transcription factor β-catenin. *JACS*, 146, 16856-16865. PMID 38848252 (*co-first authorship)
25. Lim M*, Do Cong T*, Orr LM, Toriki ES, Kile AC, Lee E, **Nomura DK** (2024) DCAF16-based covalent handle for the rational design of monovalent degraders. *ACS Central Science,* 10, 1318-1331. PMID 39071058 (*co-first authorship)

26. Gowans FA, Thach DQ, Wang Y, Altamirano Poblano BE, Dovala D, Tallarico JA, McKenna JM, Schirle M, Maimone TJ*, **Nomura DK*** (2024) Ophiobolin A covalently targets complex IV leading to mitochondrial metabolic collapse in cancer cells. *ACS Chemical Biology* 19, 1260-1270. PMID 38739449. (*co-corresponding authorship)
27. Zhang P, Munier JJ, Wiese CB, Vergnes L, Link JC, Abbasi F, Ronquillo E, Scheker K, Munoz A, Kuang Y-L, Theusch E, Lu M, Sanchez G, Oni-Orisan A, Iribarren C, McPhaul MJ, **Nomura DK**, Knowles JW, Krauss RM, Medina MW, Reue K (2024) X chromosome dosage drives statin-induced dysglycermia and mitochondrial dysfunction. *Nature Communications,*15, 5571. Doi:10.1038/s41467-024-49764-2. PMID 38956041
28. Shihadih D, Wang X, Zushin P-JH, Khodakivskyi P, Park HM, Tso E, Shiblak J, Misic A, Louie SM, Ward C, Hellerstein M, **Nomura DK**, Goun E, Urigo F, Calvisi DF, Chen X, Stahl A (2024) FATP5 is indispensable for the growth of intrahepatic cholangiocarcinoma. *Molecular Cancer Research*, 22, 585-595. PMID 38358323
29. Hong SH*, Divakaran A*, Osa A, Huang OW, Wertz IE, **Nomura DK** (2024) Exploiting the Cullin E3 ligase adaptor protein SKP1 for targeted protein degradation. *ACS Chemical Biology,* 19, 442-450. PMID 37904950 (*co-first authorship)
30. Meyers M, Cismoski S, Panidapu A, Chie-Leon B, **Nomura DK** (2024) Targeted protein degradation through recruitment of the CUL4 complex adaptor protein DDB1. *ACS Chemical Biology,* 19, 58-68. PMID 38192078
31. Davis MA, Yu VY, Fu B, Wen M, Koleski EJ, Silverman J, Berdan CA, **Nomura DK**, Chang MCY (2023) A cellular platform for production of C4 monomers. *Chemical Science* 14, 11718-11726. PMID 37920356
32. Pham VN, Bruemmer KJ, Toh JDW, Ge EJ, Tenney L, Ward CC, Fingler FA, Millington CL, Garcia-Prieto CA, Pulos-Holmes MC, Ingolia NT, Pontel LB, Esteller M, Patel KJ, **Nomura DK**, Chang CJ (2023) Formaldehyde regulates S-adenosylmethionine biosynthesis and one-carbon metabolism. *Science* 382, eabp9201. PMID 37917677
33. Zhang LH, Tang M, Tao X, Shao Q, Thomas V, Shimizu S, Kasano M, Ishikawa Y, Inukai T, **Nomura DK** (2023) Covalent targeting of glutamate cysteine ligase to inhibit glutathione synthesis. *Chembiochem,* 24, e202300371. PMID 37756477
34. Toriki ES*, Papatzimas JW*, Nishikawa K, Dovala D, Frank AO, Hesse MJ, Dankova D, Song J-G, Bruce-Smythe M, Struble H, Garcia FJ, Brittain SM, Kile AC, McGregor LM, McKenna JM, Tallarico JA, Schirle M, **Nomura DK** (2023) Rational chemical design of molecular glue degraders. *ACS Central Science*, 9, 915-926. PMID 37252349 (* co-first authorship)
35. King EA, Cho Y, Hsu NS, Dovala D, McKenna JM, Tallarico JA, Schirle M, **Nomura DK** (2023) Chemoproteomics-Enabled Discovery of a Covalent Molecular Glue Degrader Targeting NF-kB. *Cell Chemical Biology*, 30, 394-402. PMID 36898369
36. Forte N, Dovala D, Hesse MJ, McKenna JM, Tallarico JA, Schirle M, **Nomura DK** (2023) Targeted protein degradation through E2 recruitment. *ACS Chemical Biology*, 18, 897-904. PMID 36940189
37. Belcher BP, Ward CC, **Nomura DK** (2023) Ligandability of E3 ligases for targeted protein degradation applications. *Biochemistry* 62, 588-600. PMID 34473924
38. Moon P*, Zammt CM*, Shao Q*, Dovala D*, Boike L*, Henning NJ*, Knapp M*, Spradlin JN*, Ward CC*, Wolleb H*, Fuller D, Blake G, Murphy JP, Wang F, Lu Y, Moquin SA, Tandeske L, Hesse MJ, McKenna JM, Tallarico JA, Schirle M, Toste FD[#], **Nomura DK[#]** (2023) Discovery of potent pyrazoline-based covalent SARS-CoV-2 main protease inhibitors. *Chembiochem,* 24(11):e202300116. PMID 37069799 (*co-first authors; #co-corresponding authors)
39. Belcher BP, Machicao PA, Tong B, Ho E, Friedli J, So B, Bui H, Isobe Y, Maimone TJ[#], **Nomura DK[#]** (2023) Chemoproteomic Profiling Reveals that Anti-Cancer Natural Product Dankastatin B Covalently Targets Mitochondrial VDAC3. *Chembiochem,* 24, 3202300111. PMID 36964942 (#co-corresponding authors)
40. Bajaj T, Wehri E, Suryawanshi RK, King E, Pardeshi KS, Behrouzi K, Khodabakshi Z, Schulze-Gahmen U, Kumar GR, Mofrad MRK, **Nomura DK**, Ott M, Schaletzky J, Murthy N (2023) Mercapto-pyrmidines are reversible covalent inhibitors of the papain-like protease (PLpro) and inhibit SARS-CoV-2 (SCoV-2) replication. *RSC Advances*, 13, 17667-17677. PMID 37312993
41. Koo T-Y, Lai H, **Nomura DK**, Chung CY-K. (2023) *N*-acryloylindole-alkyne (NAIA) enables imaging and profiling new ligandable cysteines and oxidized thiols by chemoproteomics. *Nature Communications*, doi: https://doi.org/10.1101/2023.05.18.541312.

42. Han H, Gracia AV, Roise JJ, Boike L, Leon K, Schulze-Gahmen U, Stentzel MR, Bajaj T, Chen D, Li IC, He M, Behrouzi K, Khodabakshi Z, **Nomura DK**, Mofrad MRK, Kumar GR, Ott M, Murthy N. (2023) A covalent inhibitor targeting the papain-like protease from SARS-CoV-2 inhibits viral replication. *RSC Advances,* 13, 10636-10641. PMID 37025664

43. Benjamin DI, Brett JO, Both P, Benjamin JS, Ishak HL, Kang J, Kim S, Chung M, Arjona M, Nutter CW, Tan JH, Krishnan AK, Dulay H, Louie SM, de Morree A, **Nomura DK**, Rando TA (2023) Multiomics reveals glutathione metabolism as a driver of bimodality during stem cell aging. *Cell Metabolism* 35, 472-486. PMID 36854304

44. Henning NJ*, Boike L*, Spradlin JN, Ward CC, Liu G, Zhang E, Belcher BP, Brittain SM, Hesse M, Dovala D, McGregor LM, Veldez Misiolek R, Plasschaert LW, Rowlands DJ, Wang F, Frank AO, Fuller D, Estes AR, Randal KL, Panidapu A, McKenna JM, Tallarico JA, Schirle M, **Nomura DK** (2022) Deubiquitinase-targeting chimeras for targeted protein stabilization. *Nature Chemical Biology* 18, 412-421. PMID 35210618 (* co-first authorship)

45. Henning NJ*, Manford AG*, Spradlin JN, Brittain SM, McKenna JM, Tallarico JA, Schirle M, Rape M[#], **Nomura DK[#]** (2022) Discovery of a covalent FEM1B recruiter for targeted protein degradation applications. *Journal of the American Chemical Society* 144, 701-708. PMID 34994556 (*co-first authorship; #co-corresponding authorship)

46. Boike L*, Henning NJ*, **Nomura DK** (2022) Advances in covalent drug discovery. *Nature Reviews Drug Discovery* 21, 881-898. PMID 36008483 (*co-first authors)

47. Shin HR, Citron YR, Wang L, Tribouillard L, Goul CS, Stipp R, Sugasawa Y, Jain A, Samson N, Lim C-Y, Davis OB, Castaneda-Carpio D, Qian M, **Nomura DK**, Perera RM, Park E, Covey DF, Laplante M, Evers AS, Zoncu R (2022) Lysosomal GPCR-like protein LYCHOS signals cholesterol sufficiency to mTORC1. *Science* 377, 1290-1298. PMID 36007018

48. Maza JC, Garcia-Almedina DM, Boike LE, Hamlish NX, **Nomura DK**, Francis MB (2022) Tyrosinase-Mediated Synthesis of Nanobody-Cell Conjugates. *ACS Central Science* 8, 955-962. PMID 35912347

49. Benjamin DI, Both P, Benjamin JS, Nutter CW, Tan JH, Kang J, Machado LA, Klein JDD, de Morree A, Kim S, Liu L, Dulay H, Feraboli L, Louie SM, **Nomura DK**, Rando TA (2022) Fasting induces a highly resilient deep quiescent state in muscle stem cells via ketone body signaling. *Cell Metabolism* 34, 1-17. PMID 35584694

50. Page ACS, Scholz SO, Keenan KN, Spradlin JN, Belcher BP, Brittain SM, Tallarico JA, McKenna JM, Schirle M, **Nomura DK***, Toste FD* (2022) Photo-Brook rearrangement of acyl silanes as a strategy for photoaffinity probe design. *Chemical Science* 13, 3851-3856. PMID 35432890 (*co-corresponding author)

51. Trauner D, Fischer C, Nynke V, Peitsinis Z, Ruhmann P, Yang C, Spradlin J, Dovala D, **Nomura D**, Zhang Y (2021) De novo design of SARS-CoV-2 Main Protease Inhibitors. Synlett, 33, 458-463. PMID 35282568

52. **Nomura DK**, Dey M (2021) Advances and opportunities in targeted protein degradation. *Cell Chemical Biology* 15, 887-888. PMID 34270936

53. Spradlin JN, Zhang E, **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. *Accounts of Chemical Research.* 54, 1801-1813. PMID 33733731

54. Luo M*, Spradlin JN*, Boike L, Tong B, Brittain SM, McKenna JM, Tallarico JA, Schirle M, Maimone TJ[#], **Nomura DK[#]**. (2021) Chemoproteomics-enabled ligand discovery of covalent RNF114-based degraders that mimic natural product function. *Cell Chemical Biology* 28, 559-566. PMID 33513350 (*co-first authorship, [#] co-corresponding authorship)

55. Boike L*, Cioffi AG*, Majewski FC, Co J, Henning NJ, Jones MD, Liu G, McKenna JM, Tallarico JA, Schirle M, **Nomura DK**. (2021) Discovery of a functional covalent ligand targeting an intrinsically disordered cysteine within MYC. *Cell Chemical Biology* 28, 4-13. PMID 32966806 (*co-first authorship)

56. Tong B, Belcher BP, **Nomura DK**, Maimone TJ (2021) Chemical investigations into the biosynthesis of the gymnastatin and dankastatin alkaloids. *Chemical Science* 12, 8884-8891. PMID 34257889

57. Biering SB, Van Dis E, Wehri E, Yamashiro LH, Nguyenla X, Dugast-Darzacq C, Graham TGW, Stroumza JR, Golovkine GR, Roberts AW, Fines DM, Spradlin JN, Ward CC, Bajaj T, Dovala D, Schulze Gahmen U, Bajaj R, Fox DM, Ott M, Murthy N, **Nomura DK**, Schaletzky J, Stanley SA (2021) Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2. *ACS Infectious Diseases* 7, 2337-2351. PMID 34129317

58. Kilinc S, Paisner R, Camarda R, Gupta S, Momcilovic O, Kohnz RA, L'Etoile ND, Perera RM, **Nomura DK**, Goga A (2021) Oncogene regulated release of extracellular vesicles. *Developmental Cell* 56, 1989-2006. PMID 34118203

59. Tharp KM, Higuchi-Sanabria R, Timblin GA, Ford B, Garzon-Coral C, Schneider C, Muncie JM, Stashko C, Daniele JR, Moore AS, Frankino PA, Homentcovschi S, Manoli SS, Shao H, Richards AL, Chen KH, Hoeve JT, Ku GM, Hellerstein M, **Nomura DK**, Saiko K, Gestwicki J, Dunn AR, Krogan NJ, Swaney DL, Dillin A, Weaver VM. (2021) Adhesion-mediated mechanosignaling forces mitohormesis. *Cell Metabolism* 33,1322-1341. PMID 34019840

60. Timblin GA, Tharp KM, Ford B, Winchenster JM, Wang J, Zhu S, Khan RI, Louie SK, Iavarone AT, ten Hoeve J, **Nomura DK**, Stahl A, Saijo K (2021) Mitohormesis reprograms macrophage metabolism to enforce tolerance. *Nature Metabolism* 3, 618-635. PMID 34031590

61. Moldavski O, Zushin P-JH, Berdan CA, Van Eijkeren RJ, Jiang X, Qian M, Ory DS, Covey SF, **Nomura DK**, Stahl A, Weiss EJ, Zoncu R (2021) 4β-hydroxycholesterol is a pro-lipogenic factor that promotes SREBP1c expression and activity through Liver X-receptor. *Journal of Lipid Research*, 62, 100051. PMID 33631213

62. Cho H, Shen Q, Zhang LH, Okumura M, Kawakami A, Ambrose J, Sigoillot F, Miller HR, Gleim S, Cobos-Correa A, Wang Y, Piechon P, Roma G, Eggiman F, Moore C, Aspesi Jr. P, Mapa FA, Burks H, Ross NT, Krastel P, Hild M, Maimone TJ, Fisher DE, **Nomura DK**, Tallarico JT, Canham SM, Jenkins JL, Forrester WC (2021) CYP27A1 dependent anti-melanoma activity of limonoid natural products targets mitochondrial metabolism. *Cell Chemical Biology* 28, 1407-1419. PMID 33794192

63. Tosic I, Heppler LN, Egusquiaguirre SP, Boehnke N, Correa S, Costa DF, Grossman EA, Pal S, Richardson D, Ivanov AR, Haas-Kogan DA, **Nomura DK**, Hammond PT, Frank DA (2021) Lipidome-based targeting of STAT3-driven breast cancer cells using poly-L-glutamic acid-coated layer-by-layer nanoparticles. *Molecular Cancer Therapeutics* 20, 726-738. PMID 33536189

64. Isobe Y, Okumura M, White R, McGregor LM, Brittain SM, Jones MD, Liang X, White R, Forrester W, McKenna JM, Tallarico JA, Schirle M, Maimone TJ*, **Nomura DK*** (2020) Manumycin polyketides act as molecular glues between UBR7 and P53. *Nature Chemical Biology* 16, 1189-1198. PMID 3257277 (*co-corresponding author)

65. Tong B*, Spradlin JN*, Novaes LFT, Zhang E, Hu X, Moeller M, Brittain SM, McGregor LM, McKenna JM, Tallarico JA, Schirle M, Maimone TJ[#], **Nomura DK[#].** (2020) A nimbolide-based kinase degrader preferentially degrades oncogenic BCR-ABL. *ACS Chemical Biology* 15, 1788-1794. PMID 32568522 (*co-first authorship; # co-corresponding authorship)

66. Tong B*, Luo M*, Xie Y, Spradlin JN, Tallarico JA, McKenna JM, Schirle M, Maimone TJ[#], **Nomura DK[#].** (2020) Bardoxolone Conjugation Enables Targeted Protein Degradation of BRD4. *Scientific Reports* 10, 15543. PMID 32968148 (*co-first authorship; # co-corresponding authorship)

67. Manford AG, Rodriguez-Perez F, Shih KY, Shi Z, Berdan CB, Choe M, Titov DV, **Nomura DK**, Rape M (2020) A cellular mechanism to detect and alleviate reductive stress. *Cell* 183, 46-61. PMID 32941802

68. Sponton CH, Hosonoro T, Taura J, Jedrychowski MP, Yoneshiro T, Wang Q, Takahashi M, Matsui Y, Ikeda K, Oguri Y, Tajima K, Shinoda K, Pradham R, Chen Y, Brown Z, Roberts LS, Ward CC, Taoka H, Yokohama Y, Watanabe M, Karasawa H, **Nomura DK**, Kajimura S (2020) The regulation of glucose and lipid homeostasis via PLTP as a mediator of BAT-liver communication. *EMBO Reports* 21, e49828. PMID 32672883

69. Ibars M, Maier MT, Yulyaningsih E, Perez L, Cheang R, Vihelmsson A, Louie SM, Wegner SA, Yuan X, Eltzschig HK, Hopf FW, **Nomura DK**, Koliwad SK, Xu AW (2020) Neuronal modulation of hepatic lipid accumulation induced by binge-like drinking. *American Journal of Physiology: Endocrinology and Metabolism* 318, E655-E666. PMID 32045262

70. Coles GL, Cristea S, Webber JT, Levin RS, Moss SM, He A, Sangodkar J, Hwang YC, Arand J, Drainas AP, Mooney NA, Demeter J, Spradlin JN, Mauch B, Le V, Shue YT, Ko JH, Lee MC, Kong C, **Nomura DK**, Ohlmeyer M, Swaney DL, Korgan N, Jackson PK, Narla G, Gordan JD, Shokat K, Sage J (2020) Unbiased proteomic profiling uncovers a targetable GNAS/PKA/PP2A axis in small cell lung cancer stem cells. *Cancer Cell* 38, 129-143. PMID 32521271

71. Chung CY-S*, Shin HR*, Berdan CA, Ford B, Ward CC, Olzmann JA, Zoncu R[#], **Nomura DK[#]** (2019) Covalent targeting of the vacuolar H^+-ATPase activates autophagy via mTORC1 inhibition. *Nature Chemical Biology* 15, 776-785. PMID 31285595 (*co-first authorship; #co-corresponding authorship)

72. Spradlin JN, Hu X, Ward CC, Brittain SM, Jones MD, Ou L, To M, Proudfoot A, Ornelas E, Woldegiorgis M, Olzmann JA, Bussiere DE, Thomas JR, Tallarico JA, McKenna JM, Schirle M, Maimone TJ*, **Nomura DK*** (2019) Harnessing the anti-cancer natural product nimbolide for targeted protein degradation. *Nature Chemical Biology* 15, 747-755. PMID 31209351 (*co-corresponding authors)

73. Ward CC, Kleinman JI, Chung CYS, Kim K, Petri Y, Lee PS, Thomas JR, Tallarico JA, McKenna JM, Schirle M, **Nomura DK** (2019) Covalent ligand screening uncovers a RNF4 E3 ligase recruiter for targeted protein degradation applications. *ACS Chemical Biology* 14, 2430-2440. PMID 31059647

74. Berdan CA, Ho R, Lehtola HS, To M, Hu X, Huffman TR, Petri Y, Altobelli CR, Demeulenaere SG, Olzmann JA, Maimone TJ*, **Nomura DK*** (2019) Parthenolide covalently targets and inhibits focal adhesion kinase in breast cancer cells. *Cell Chemical Biology* 26, 1027-1035. PMID 31080076 (*co-corresponding authorship)

75. Ahyong V, Berdan CA, Burke TP, **Nomura DK**, Welch MD (2019) A metabolic dependency for host isoprenoids in the obligate intracellular pathogen *Rickettsia parkeri* underlies a sensitivity to the statin class of host-targeted therapeutics. mSphere 4 (6), e00536-19. PMID 31722991

76. Bersuker K, Hendricks J, Li Z, Magtanong L, Ford B, Tang PH, Roberts MA, Tong B, Maimone TJ, Zoncu R, Bassik MC, **Nomura DK**, Dixon SJ, Olzmann JA (2019) The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. *Nature* 575, 688-692. PMID 31634900

77. Lim C-Y, Davis O, Shin H, Zhang J, Berdan CB, Jiang X, Counihan JL, Ory D, Nomura DK, Zoncu R (2019) ER-lysosome contacts enable cholesterol sensing by mTORC1 and drive aberrant growth signaling in Niemann-Pick type C. *Nature Cell Biology* 21, 1206-1218. PMID 31548609

78. Lee K, Yesilkanal AE, Wynne JP, Frakenberger C, Liu J, Yan J, Elbaz M, Rabe DC, Rustandy FD, Tiwari P, Grossman EA, Hart PC, Kang C, Sanderson SM, Andrade J, **Nomura DK**, Bonini MG, Locasale JW, Rosner MR (2019) Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism. *Nature* 568, 254-258. PMID 30842661

79. Watt MJ, Clark AK, Selth LA, Haynes VR, Lister N, Rebello R, Porter LH, Niranjan B, Whitby ST, Lo J, Huang C, Schittenhelm RB, Anderson KE, Furic L, Wijayaratne PR, Matzaris M, Montgomer MK, Parpargiris M, Norden S, Febbraio M, Risbridger GP, Frydenberg M, **Nomura DK**, Taylor RA. (2019) Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. *Science Translational Medicine* 11(478):eaau5758. PMID 3078288

80. Herber CB, Krause WC, Wang L, Bayrer JR, Li A, Schmitz M, Fields A, Ford B, Zhang Z, Reid MS, **Nomura DK**, Nissenson RA, Correa SM, Ingraham HA (2019) Estrogen signaling in arcuate *Kiss1* neurons suppresses a sex-dependent female circuit promoting dense strong bones. *Nature Communications*, 10, 163. PMID 30635563

81. Magtanong L, Ko P-J, To M, Cao JY, Tarangelo AN, Ward CC, Cho KY, Patti GJ, **Nomura DK**, Olzmann JA, Dixon SJ (2019) Exogenous monounsaturated fatty acids suppress non-apoptotic cell death. *Cell Chemical Biology* 26, 420-432. PMID 30686757

82. Stazi G, Battistelli C, Piano V, Mazzone R, Marrocco B, Marchese S, Louie SM, Zwergel C, Antonini L, Patsilinakos A, Ragno R, Viviano M, Sbardella G, Ciogli A, Fabrizi G, Cirilli R, Strippoli R, Marchetti A, Tripodi M, **Nomura DK**, Mattevi A, Mai A, Valente S (2019) Development of alky glycerone phosphate synthase inhibitors: Structure-activity relationship and effects on ether lipids and epithelial-to-mesechymal transition in cancer cells. *European Journal of Medicinal Chemistry* 163, 722-735. PMID 30576903

83. Volkmar N, Thezenas M-L, Louie SM, Juszkiewicz S, **Nomura DK**, Hegde RS, Kessler BM, Christianson JC (2019) The ER membrane protein complex (EMC) promotes biogenesis of sterol-related enzymes maintaining cholesterol homeostasis. *Journal of Cell Science* 132, pii:jcs223453. PMID 30578317

84. **Nomura DK** (2018) Virtual Issue on the Work of John Casida. *Chemical Research in Toxicology* 31, 637-638. PMID 30080400

85. **Nomura DK*** and Maimone TJ*. (2018) Target identification of bioactive covalently-acting natural products. *Current Topics in Microbiology and Immunology* 420, 351-374. PMID 30105423 (*co-corresponding authorship)

86. Counihan JL*, Wiggenhorn A*, Anderson KE, **Nomura DK**. (2018) Chemoproteomics-enabled covalent ligand screening reveals ALDH3A1 as a lung cancer target. *ACS Chemical Biology* 13, 1970-1977. (*co-first authors) PMID 300004670

87. Counihan JL, Grossman EA, **Nomura DK**. (2018) Cancer metabolism: current understanding and therapies. *Chemical Reviews* 118, 6893-6923. PMID 29939018

88. Long JZ, Roche AM, Berdan CA, Louie SM, Roberts AJ, Svensson KJ, Dou FY, Bateman LA, Mina AI, Deng Z, Jedrychowski MP, Lin H, Kamenecka T, Asara JM, Griffin PR, Banks AS, **Nomura DK,** Spiegelman BM. (2018) Ablation of PM20D1 reveals N-acyl amino acid control of metabolism and nociception. *Proceedings of the National Academy of Sciences, U.S.A.* 115, E6937-E6945. PMID 29967167

89. Fernandez RF, Kim SQ, Zhao Y, Foguth RM, Weera MM, Counihan JL, **Nomura DK**, Chester JA, Cannon JR, Ellis JM (2018) Acyl-CoA synthetase 6 enriches the neuroprotective omega-3 fatty acid DHA in the brain. *Proceedings of the National Academy of Sciences, U.S.A.* 115, 12525-12530. PMID 30327559
90. Zhou M, Ford B, Lee D, Huen K, Tran Y, Bradman A, Gunier R, Eskenazi B, **Nomura DK**, Holland NT (2018) Metabolomic markers of phthalate exposure in plasma and urine of pregnant women. *Frontiers in Public Health* 6, 298. PMID 30406068
91. Wallace M, Green CR, Roberts LS, Lee YM, McCarville J, Sanchez-Gurmaches J, Meurs N, Gengatharan JM, Hover J, Phillips SA, Ciaraldi TP, Guertin DA, Cabrales P, Ayres JS, **Nomura DK**, Loomba R, Metallo CM (2018) Enzyme promiscuity drives branched-chain fatty acid synthesis in adipose tissue. *Nature Chemical Biology* 14, 1021-1031. PMID 30327559
92. Van Dalfsen KM, Hodapp S, Keskin A, Otto GM, Berdan CA, Higdon A, Cheunkarndee T, **Nomura DK**, Jovanovic M, Brar GA. (2018) Global proteome remodeling during ER stress involves Hac1-driven expression of long undecoded transcript isoforms. *Developmental Cell* 46, 219-235. PMID 30016623
93. Tam AB, Roberts LS, Chandra V, Rivera IG, **Nomura DK**, Forbes DJ, Niwa M. (2018) The UPR activator ATF6 responds to proteotoxic and lipotoxic stress by distinct mechanisms. *Developmental Cell* 46, 327-343. PMID 30086303
94. Patra KC, Kato Y, Mizukami Y, Widholz S, Boukhali M, Revenco I, Grossman EA, Ji F, Sadreyev RI, Liss AS, Screaton RA, Sakamoto K, Ryan DP, Mino-Kenudson M, Fernandez-del Castillo C, **Nomura DK**, Haas W, Bardeesy N. (2018) Mutant GNAS drives pancreatic tumorigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. *Nature Cell Biology* 20, 811-822. PMID 29941929
95. Maier MT, Vilhelmsson A, Louie SM, Vagena E, **Nomura DK**, Koliwad SK, Xu AW. (2018) Regulation of hepatic lipid accumulation and distribution by Agouti-relation protein in male mice. *Endocrinology* 159, 2408-2420. PMID 29750244
96. Lin H, Long JZ, Roche AM, Svensson KJ, Dou F, Chang MR, Srutzenberg T, Ruiz C, Cameron MD, Novick SJ, Berdan CA, Louie SM, **Nomura DK**, Spiegelman BM, Griffin PR, Kamenecka TM. (2018) Discovery of hydrolysis-resistant isoindoline N-acyl amino acid analogs that stimulate mitochondrial respiration. *Journal of Medicinal Chemistry* 61, 3224-3230. PMID 29533650
97. Tomin T, Fritz K, Gindlhuber J, Waldherr L, Pucher B, Thallinger GG, **Nomura DK**, Schittmayer M, Birner-Gruenberger R. (2018) Deletion of adipose triglyceride lipase links triacylglycerol accumulation to a more aggressive phenotype in A549 lung carcinoma cells. *Journal of Proteome Research* 17, 1415-1425. PMID 29457907
98. Prasse C, Ford B, **Nomura DK,** Sedlak DL. (2018) Unexpected transformation of dissolved phenols to toxic dicarbonyls by hydroxyl radicals and UV light. *Proceedings of the National Academy of Sciences, USA.* 115, 2311-2316. PMID 29463747
99. Nnadi CI, Jenkins ML, Gentile DR, Bateman LA, Zaidman D, Ballus TE, **Nomura DK**, Burke JE, Shokat KM, London N. (2018) Novel K-Ras G12C switch-II covalent binders destabilize Ras and accelerate nucleotide exchange. *Journal of Chemical Information and Modeling* 57, 464-471. PMID 29320178
100. Gibeaux R, Acker R, Kitaoka M, Georgiou G, van Kruijsbergen I, Ford B, Marcotte EM, **Nomura DK**, Kwon T, Veenstra GJC, Heald R. (2018) Paternal chromosome loss and metabolic crisis contribute to hybrid inviability in *Xenopus*. *Nature* 553, 337-341. PMID 29320479
101. Bersuker K, Peterson CWH, To M, Sahl SJ, Savikhin V, Grossman EA, **Nomura DK**, Olzmann JA. (2018) A proximity labeling strategy provides insights into the composition and dynamics of lipid droplet proteomes. *Developmental Cell* 44, 97-112. PMID 29275994
102. Lue JW, Podolak J, Kolahi K, Cheng L, Rao S, Garg D, Xue CH, Rantala JK, Tyner JW, Thornburh KL, Martinez-Acevedo A, Liu JJ, Amling CL, Truillet C, Louie SM, Anderson KE, Evans MJ, O'Donnell VB, **Nomura DK**, Drake JM, Ritz A, Thomas GV. (2017) Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade. *Genes and Development* 31, 2067-2084. PMID 29138276
103. De Leon JA, Qiu J, Nicolai CJ, Counihan JL, Barry KC, Xu L, Lawrence RE, Castellano BM, Zoncu R, **Nomura DK**, Luo Z-Q, Vance RE. (2017) Positive and negative regulation of the master metabolic regulator mTORC1 by two families of *Legionella pneumophila* effectors. *Cell Reports* 21, 2031-2038. PMID 29166595
104. Grossman E*, Ward CC*, Spradlin JN, Bateman LA, Huffman TR, Miyamoto DK, Kleinman JI, **Nomura DK.** (2017) Covalent ligand discovery against druggable hotspots targeted by anti-cancer natural products. *Cell Chemical Biology* 24, 1368-1376. PMID 28919038 (*co-first authorship)

105. Anderson KE, To M, Olzmann JA, **Nomura DK**. (2017) Chemoproteomics-enabled covalent ligand screening reveals a thioredoxin-caspase 3 interaction disruptor that impairs breast cancer pathogenicity. *ACS Chemical Biology* 12, 2522-2528. PMID 28892616

106. Chen T-C, Benjamin DI, Kuo T, Lee RA, Li M-L, Mar D, Costello DE, **Nomura DK**, Wang J-C. (2017) Glucocorticoid-Angiopoietin-like 4-Ceramide Axis induces insulin resistance. *Science Signaling* 10, eaai7905. PMID 28743803

107. Chomvong K, Benjamin DI, **Nomura DK**, Cate JH. Cellobiose consumption uncouples extracellular glucose sensing and glucose metabolism in Saccharomyces cerevisiae. *mBio* 8, e00855-17.

108. Nguyen TB, Louie SM, Daniele J, Tran Q, Dillin A, Zoncu R, **Nomura DK**, Olzmann JA. (2017) DGAT1-dependent lipid droplet biogenesis protects mitochondrial function during starvation-induced autophagy. *Developmental Cell* 42, 9-21. PMID 28697336

109. Ward CC, Kleinman J, **Nomura DK**. (2017) NHS-esters as versatile reactivity-based probes for mapping proteome-wide ligandable hotspots. *ACS Chemical Biology* 12, 1478-1483. PMID 28445029

110. Bateman LA[#], Nguyen TB[#], Roberts AM[#], Miyamoto DK, Ku W-M, Huffman TR, Petri Y, Heslin MJ, Contreras CM, Skibola CF, Olzmann JA*, **Nomura DK*.** (2017) Chemoproteomics-enabled covalent ligand screen reveals a cysteine hotspot in Reticulon 4 that impairs ER morphology and cancer pathogenicity. *Chemical Communications* 53, 7234-7237. PMID 28352901 (#co-first authors; *co-corresponding author)

111. Roberts LS, Yan P, Bateman LA, **Nomura DK.** (2017) Mapping novel metabolic nodes targeted by anti-cancer drugs that impair triple-negative breast cancer pathogenicity. *ACS Chemical Biology* 12, 1133-1140. PMID 28248089

112. Bateman LA, Ku W-M, Heslin MJ, Contrearas CM, Skibola CF, **Nomura DK**. (2017) ASS1 is an important metabolic regulator of colorectal cancer. *ACS Chemical Biology* 12, 905-911. PMID 28229591

113. Castellano, B.M., Thelen, A.M., Moldavski O, Feltes M, van der Welle R, Mydock-McGrane L, Jiang X, van Eijkeren RJ, Davis OB, Louie SM, Perera RM, Covey D, **Nomura DK**, Ory DS, Zoncu R. (2017) Lysosomal cholesterol activates mTORC1 via an SLC38A9-Niemann Pick C1 signaling complex. *Science* 355, 1306-1311. PMID 28336668

114. Roberts AM, Miyamoto DK, Huffman TR, Bateman LA, Ives AN, Akopian D, Heslin MJ, Contreras CM, Rape M, Skibola CF, **Nomura DK**. (2017) Chemoproteomic screening of covalent ligands reveals UBA5 as a novel pancreatic cancer target. *ACS Chemical Biology* 12, 899-904. PMID 28186401

115. Counihan JL, Duckering M, Dalvie E, Ku W-m, Bateman LA, Fisher KJ, **Nomura DK.** (2017) Mapping proteome-wide reactivity of the widely used herbicide acetochlor in mice. *ACS Chemical Biology* 12, 635-642. PMID 28094496

116. Whang MI, Taveras RM, Benjamin DI, Kattah MG, Advincula R, **Nomura DK**, Debnath J, Malynn BA, Ma A. (2017) The ubiquitin binding protein TAX1BP mediates autophagasome induction and the metabolic transition of activated T cells. *Immunity* 46, 405-420. PMID 28314591

117. Anderton B, Camarda R, Balkrishnan S, Balakrishnan A, Kohnz RA, Lim L, Evason KJ, Momcilovic O, Kruttwig K, Huang Q, Xu G, **Nomura DK**, Goga A. (2017) MYC-driven inhibition of the glumate-cysteine ligase promotes glutathione depletion in liver cancer. *EMBO Report* 18, 569-585. PMID 28219903

118. Ford B, Bateman LA, Gutierrez-Palominos L, Park R, **Nomura DK.** (2017) Mapping proteome-wide targets of glyphosate in mice. *Cell Chemical Biology* 24, 133-140. PMID 28132892

119. Ruby MA, Massart J, Hunerdosse DM, Schonke M, Correia JC, Louie SM, Ruas JL, Naslund E, **Nomura DK,** Zierath JR. (2017) Human carboxylesterase 2 reverses obesity-induced diacylglycerol accumulation and glucose intolerance. *Cell Reports* 18, 636-646. PMID 28099843

120. Roberts AM, Ward CC, **Nomura DK**. (2017) Activity-based protein profiling for mapping and pharmacologically interrogating proteome-wide ligandable hotspots. *Current Opinion in Biotechnology* 43, 25-33. PMID 27568596

121. To M, Peterson CWH, Roberts MA, Counihan JL, Wu TT, Forster MS, **Nomura DK**, Olzmann JA. (2017) Lipid disequilibrium disrupts ER proteostasis by impairing ERAD substrate glycan trimming and dislocation. *Molecular Biology of the Cell* 28, 270-284. PMID 27881664

122. Kim H-E, Grant AR, Simic MS, Kohnz RA, **Nomura DK**, Durieux J, Riera CE, Sanchez M, Kapernick E, Wolff Suzanne, Dillin A (2016) Lipid biosynthesis coordinates a mitochondrial-to-cytosolic stress response. *Cell* 166, 1539-1552. PMID 27568596

123. Sogi K, Holsclaw C, Fragiadakis G, **Nomura DK**, Leary J, Bertozzi C. (2016) Biosynthesis and regulation of sulfomenaquinone, a metabolite associated with virulence in Mycobacterium tuberculosis. *ACS Infectious Diseases* 2, 800-806. PMID 27933784

124. Braverman J, Sogi KM, Benjamin D, **Nomura DK**, Stanley SA. (2016) HIF-1alpha is an essential mediator of IFA-gamma-dependent immunity to Mycobacterium tuberculosis. Journal of Immunology doi: 10.4049/jimmunol.1600266. PMID 27430718
125. Kohnz RA, Roberts, LS, DeTomaso D, Badyopadhyay S, Yosef N, **Nomura DK**. (2016) Protein sialylation regulates a gene expression signature that promotes breast cancer cell pathogenicity. *ACS Chemical Biology 11,* 2131-2139. PMID 27380425
126. Long JZ, Svensson KJ, Bateman LA, Lin H, Kamenecka T, Lokurkar IA, Lou J, Rao RR, Chang MT, Jedrychowski MP, Paolo J, Griffin PR, **Nomura DK***, Spiegelman BM* (2016) PM20D1 secretion by thermogenic adipose cells regulates lipidated amino acid uncouplers of mitochondrial respiration. *Cell* 166, 424-435. PMID 27374330 (*co-corresponding authorship)
127. Chomvong K, Bauer S, Benjamin DI, Li X, **Nomura DK**, Cate JHD. (2016) Bypassing the pentose phosphate pathway: Towards modular utilization of xylose. *Plos One* 11, e0158111. PMID 27336308
128. Louie SM, Grossman EA, Crawford LA, Ding L, Camarda R, Huffman TR, Miyamoto DK, Goga A, Weerapana E, **Nomura DK**. (2016) GSTP1 is a driver of triple-negative breast cancer cell metabolism and pathogenicity. *Cell Chemical Biology* 5, 567-578. PMID 27185638
129. Zhang J, Medina-Cleghorn D, Bernal-Mizrachi L, Bracci PM, Hubbard A, Conde L, Riby J, **Nomura DK,** Skibola C (2016) The potential relevance of the endocannabinoid, 2-arachidonoylglycerol, in diffuse large B-cell lymphoma. *Oncoscience* 3, 31-41. PMID 26973858
130. Nikkanen J, Forsstrom S, Euro L, Paetau I, Kohnz RA, Wang L, Chilov D, Viinamaki J, Roivainen A, Marjamaki P, Liljenback H, Ahola S, Buzkova J, Terzioglu M, Khan NA, Pirnes-Karhu S, Paetau A, Lonnqvist T, Sajantila A, Isohanni P, Tyynaismaa H, **Nomura DK**, Battersby B, Velagapudi V, Carroll CJ, Suomalainen A (2016) Mitochondrial DNA replication defects disturb cellular dNTP pools and remodel one-carbon metabolism. *Cell Metabolism* 23, 635-648. PMID 26924217
131. **Nomura DK,** Casida JE (2016) Lipases and their inhibitors in health and disease. *Chemico-Biological Interactions* 259, 211-222. PMID 27067293
132. Camarda R, Zhou AY, Kohnz RA, Balakrishnan S, Mahieu C, Anderton B, Eyob H, Kajimura S, Tward A, Krings G, **Nomura DK**, Goga A. (2016) Inhibition of fatty-acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. *Nature Medicine* 22, 427-432. PMID 26950360.
133. Saghatelian A, **Nomura DK**, Weerapana E (2016) Omics: The maturation of chemical biology. *Current Opinions in Chemical Biology* 30: v-vi. PMID 26739665
134. Counihan JC, Ford B, **Nomura DK**. (2016) Mapping Proteome-Wide Interactions of Reactive Chemicals using Chemoproteomic Platforms. *Current Opinions in Chemical Biology* 30, 68-76. PMID 26647369
135. Medina-Cleghorn D, Bateman LA, Ford B, Heslin A, Fisher KJ, Dalvie ED, **Nomura DK.** (2015) Mapping proteome-wide targets of environmental chemicals using reactivity-based chemoproteomic platforms. *Chemistry and Biology* 22, 1394-1405. PMID26496688
136. Piano V[#], Benjamin DI[#], Valente S, Nenci S, Mai A, Aliverti A, **Nomura DK***, Mattevi A*. (2015) Discovery of inhibitors for the ether lipid-generating enzyme AGPS as anti-cancer agents. *ACS Chemical Biology* 10, 2589-2597. PMID 26322624 ([#]co-first authors; * co-corresponding authors).
137. Queiroz A, Medina-Cleghorn D, Marjanovic O, **Nomura DK**, Riley LW. (2015) Comparative metabolic profiling of *Mycobacterium tuberculosis*: cell wall lipid reorganization as a virulence factor. *Pathogens and Disease* 73, ftv066. PMID26319139.
138. Sanchez-Alavez M, Nguyen W, Mori S, Moroncini G, Viader A, **Nomura DK**, Cravatt BF, Conti B. (2015) Monoacylglycerol lipase regulates fever response. *Plos One* 10, e0134437. PMID: 26287872.
139. Kohnz RA, Mulvihill MM, Chang JW, Hsu K-L, Sorrentino A, Cravatt BF, Bandyopadhyay S, Goga A, **Nomura DK**. (2015) Activity-based protein profiling of oncogene-driven changes in metabolism reveals PAFAH1B2 and 1B3 as broad-spectrum cancer therapy targets. *ACS Chemical Biology* 10, 1624-1630. PMID: 25945974.
140. Benjamin DI, Li DS, Lowe, W, Heuer T, Kemble G, **Nomura DK**. (2015) Diacylglycerol metabolism and signaling is a predictive and driving force underlying FASN inhibitor sensitivity in cancer cells. *ACS Chemical Biology* 10, 1616-1623. PMID: 25871544
141. Rashidian J, Le Scolan E, Ji X, Mulvihill MM, **Nomura DK**, Luo K. (2015) Ski regulates Hippo and TAZ signaling to suppress breast cancer progression. *Science Signaling* 10, ra14. PMID: 25670202
142. Anderson CM, Kazantzis M, Wang J, Venkatraman S, Goncalves RLS, Quinlan CL, Ng R, Jastroch, M, Benjamin DI, Nie B, Herber C, Van A-AN, Park MK, Yun D, Chan K, Yu A, Vuong P, Febbraio M, **Nomura**

DK, Napoli JL, Brand MD, Stahl A. (2015) Dependence of brown adipose tissue function on CD36-mediated coenzyme Q uptake. *Cell Reports* 10, 505-515. PMID 25620701

143. Chang JW, Zuhl AM, Speers AE, Niessen S, Brown SJ, Mulvihill MM, Fan YC, Spicer TP, Southern M, Scampavia L, Fernandez-Vega V, Dix MM, Cameron MD, Hodder PS, Rosen H, **Nomura DK**, Kwon O, Hsu K-L, Cravatt BF. (2015) A selective inhibitor of platelet-activating factor acetylhydrolases 1b2 and 1b3 that impairs cancer cell survival. *ACS Chemical Biology* 10, 925-932. PMID: 25602368

144. Lysenko LV, Kim J, Henry C, Tyrtyshnaia A, Kohnz RA, Madamba F, Simon GM, Kleschevnikova NE, **Nomura DK**, Ezekowitz RAB, Kleschevnikov AM. (2014) Monoacylglycerol lipase inhibitor JZL184 improves behavior and neural properties in aged Ts65Dn mice, a model of Down Syndrome. *Plos One* 9, e114521. PMID: 25474204.

145. Valdearcos M, Robblee M, Benjamin DI, **Nomura DK**, Xu AW, Koliwad SK. (2014) Microglia Dictate the Impact of Saturated Fat Consumption on Hypothalamic Inflammation and Neuronal Function. *Cell Reports* 9, 1-15. PMID: 25497089

146. Hunerdosse D, Morris PJ, Miyamoto DK, Fisher KJ, Bateman LA, Ghazaleh J, Zhong S, **Nomura DK**. (2014) Chemical Genetics Screening Reveals KIAA1363 as a Cytokine-Lowering Target. *ACS Chemical Biology* 9, 2905-2913. PMID: 25343321.

147. Medina-Cleghorn D, **Nomura DK**. (2014) Exploring metabolic pathways and regulation through functional chemoproteomic and metabolomic platforms. *Chemistry & Biology* 21, 1171-1184. PMID: 25237861.

148. Mulvihill MM, **Nomura DK**. (2014) Metabolomic Strategies to Map Functions of Metabolic Pathways. *AJP Metabolism and Endocrinology* 307, E237-E244. PMID: 24918200

149. Latimer LN, Lee MR, Medina-Cleghorn D, Kohnz RA, **Nomura DK**, Dueber JE. (2014) Employing a combinatorial expression approach to characterize xylose utilization in *Saccharomyces cerevisiae*. *Metabolic Engineering* 25, 20-29. PMID: 24930894.

150. Mulvihill MM, Benjamin DI, LeScolan E, Ji X, Shieh A, Green M, Narasimhalu T, Morris PJ, Luo K, **Nomura DK.** (2014) Metabolic Profiling Reveals PAFAH1B3 as a critical driver of breast cancer pathogenicity. *Chemistry & Biology* 21, 831-840. PMID: 24954006

151. Benjamin DI, Louie S, Mulvihill MM, Kohnz RA, Li DS, Chan LG, Sorrentino A, Bandhyopadhyay S, Cozzo A, Ohiri A, Goga A, Ng-SW, **Nomura DK**. (2014) Inositol phosphate recycling regulates glycolytic and lipid metabolism that drives cancer aggressiveness. *ACS Chemical Biology* 20, 1340-1350. PMID: 24738946

152. Kohnz RK, **Nomura DK**. (2014) Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids. *Chemical Society Reviews* 43, 6859-6869. PMID: 24676249

153. Morris PJ*, Medina-Cleghorn D*, Heslin A, King S, Orr J, Krauss RM, **Nomura DK.** (2014) Organophosphorus flame retardants inhibit specific liver carboxylesterases and cause serum hypertriglyceridemia. *ACS Chemical Biology* 9, 1097-1103. (*authors contributed equally to the work) PMID: 24597639

154. Hunerdosse D, **Nomura DK.** (2014) Activity-based proteomic and metabolomic approaches for understanding metabolism. *Current Opinion in Biotechnology* 28C, 116-126. PMID 24594637

155. Poole D, Lee M, Tso P, Bunnett N, Yo S, Lieu T, Shiu A, Wang J-C, **Nomura DK**, and Aponte GW. (2014) Feeding dependent activation of enteric cells and sensory neurons by lymphatic fluid: evidence for a neurolymphocrine system. *AJP-Gastrointestinal and Liver Physiology* 306, G686-G698. PMID: 24578341

156. Dominguez E, Galmozzi A, Chang JW, Hsu K-L, Pawlak J, Li W, Godio C, Thomas J, Partida D, Niessen S, O'Brien PE, Russell AP, Watt MJ, **Nomura DK**, Cravatt BF, Saez E. (2014) Integrated phenotypic screening and activity-based proteomics defines a role for carboxylesterase 3 in obesity and diabetes. *Nature Chemical Biology* 10, 113-121. PMID: 24362705

157. Medina-Cleghorn D, Heslin A, Morris PJ, Mulvihill MM, **Nomura DK**. (2014) Multidimensional profiling platforms reveal metabolic dysregulation caused by organophosphorus pesticides. *ACS Chemical Biology* 9, 423-432. PMID: 24205821

158. **Nomura DK**, Cravatt BF. (2013) Lipid Metabolism in Cancer. *Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids* 1831, 1497-1498. PMID: 23921253

159. Benjamin DI, Cozzo A, Ji X, Roberts LS, Louie SM, Luo K, **Nomura DK**. (2013) The ether lipid generating enzyme AGPS alters the balance of structural and signaling lipids that fuel cancer pathogenicity. *Proceedings of the National Academy of Sciences, USA* 110, 14912-14917. PMID: 23980144

160. Louie SM*, Roberts LS*, Mulvihill MM, Luo K, **Nomura DK.** (2013) Cancer cells incorporate and remodel exogenous fatty acids into structural and oncogenic signaling lipids. *Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids* 1831, 1566-1572. PMID: 23872477 (* authors contributed equally to the work)

161. Louie SM, Roberts LS, **Nomura DK.** (2013) Mechanisms linking obesity and cancer. *Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids* 1831, 1499-1508. PMID: 23470257

162. Medina-Cleghorn D, **Nomura DK.** (2013) Chemical Approaches to Study Metabolic Networks. *Pflugers Archive* 465,427-440. PMID: 23296751

163. Cao Z, Mulvihill MM, Mukhopadhyay P, Xu H, Erdelyi K, Hao E, Holovac E, Hasko G, Cravatt BF, **Nomura DK[#]**, Pal Pacher[#]. (2013) Monoacylglycerol lipase controls endocannabinoid and eicosanoid signaling and hepatic injury in mice. *Gastroenterology* 144, 808-817. PMID: 23295443 (# co-corresponding authors)

164. Mulvihill MM, **Nomura DK**. (2013) Therapeutic Potential of Monoacylglycerol Lipase Inhibitors. *Life Sciences* 92, 492-497. PMID: 23142242

165. Morrison BE, Garibaldi Marcondes MC, **Nomura DK**, Sanchez-Alavez M, Saar I, Bartfai T, Maher P, Sugama S, Conti B. (2012) IL-13Ralpha1 expression in dopaminergic neurons contributes to their oxidative stress-mediates loss following chronic systemic treatment with LPS. *Journal of Immunology* 189, 5498-5502. PMID: 23169588

166. Benjamin DI, Cravatt BF, **Nomura DK**. (2012) Global Profiling Strategies towards Mapping Dysregulated Metabolic Pathways in Cancer. *Cell Metabolism* 16, 565-567. PMID: 23063552

167. Piro JR, Benjamin DI, Duerr JM, Pi YQ, Gonzales C, Schwartz JW, **Nomura DK[#]**, Samad TA[#]. (2012) A Dysregulated Endocannabinoid-Eicosanoid Network Supports Pathogenesis in a Mouse Model of Alzheimer's Disease. *Cell Reports* 1, 617-623. PMID: 22813736 (# co-corresponding author)

168. **Nomura DK[#]**, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC, Ward AM, Hahn YK, Lichtman AH, Conti B, Cravatt BF[#]. (2011) Endocannabinoid hydrolysis generates brain eicosanoids that promote neuroinflammation. *Science* 334, 809-813. PMID: 22021672 (# co-corresponding author)

169. Ruby MA, **Nomura DK**, Hudak CSS, Barber A, Casida JE, Krauss RM. (2011) Overactive endocannabinoid signaling induces hepatic steatosis, insulin resistance, and global transcriptional changes. *Plos One* 6, e26415. PMID: 22073164

Undergraduate/Graduate/Postdoctoral Work (2002-2011)

170. **Nomura DK[#]**, Lombardi DP, Chang JW, Niessen S, Ward AM, Long JZ, Hoover HH, Cravatt BF[#]. (2011) Monoacylglycerol lipase exerts bidirectional control over endocannabinoid and fatty acid pathways to support prostate cancer pathogenesis. *Chemistry & Biology* 18, 848-856. PMID: 21802006 (# co-corresponding author)

171. Ramesh D, Ross GR, Schlosburg JE, Abdullah RA, Kinsey SG, Long JZ, **Nomura DK**, Sim-Selley LJ, Cravatt BF. (2011) Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated withdrawal symptoms in mice. *Journal of Pharmacology and Experimental Therapeutics* 339, 173-185. PMID: 21719468

172. Kinsey SG, **Nomura DK**, O'Neal ST, Long JZ, Cravatt BF, Lichtman AH. (2011) Inhibition of monoacylglycerol lipase (MAGL) attenuates NSAID-induced gastric hemorrhages in mice. *Journal of Pharmacology and Experimental Therapeutics* 338, 795-802. PMID: 21659471

173. Chang JW, **Nomura DK**, Cravatt BF. (2011) A potent and selective inhibitor of KIAA1363/AADACL1 that impairs prostate cancer pathogenesis. *Chemistry & Biology* 18, 476-484. PMID: 21513884

174. Ahn K, Smith SE, Liimata MB, Sadagopan N, Dudley D, Young T, Wren P, Zhang Y, Swaney S, Van Becelaere K, Blankman JL, **Nomura DK**, Bhattachar SN, Stif C, Nomanbhoy TK, Weerapana E, Johnson DS, Cravatt BF. (2011) Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective FAAH inhibitor that reduces inflammatory and noninflammatory pain. *Journal of Pharmacology and Experimental Therapeutics* 338, 114-124. PMID: 21505060

175. **Nomura DK[#]**, Casida JE[#]. (2011) Activity-based protein profiling of organophosphorus and thiocarbamate pesticides reveals multiple secondary targets in the mammalian nervous system. *Journal of Agricultural and Food Chemistry* 59, 2808-2815. PMID: 21341672 (# co-corresponding author)

176. Nicolaou KC, Sanchini S, Sarlah D, Lu G, Wu R, **Nomura DK**, Cravatt BF, Cubitt B, de la Torre JC, Hessell AJ, Burton DR. (2011) Design, synthesis and biological evaluation of a biyouyanagin compound library. *Proceedings of the National Academy of Sciences, USA* 108, 6715-6720. PMID: 21245351

177. Bachovchin DA, Mohr JT, Speers AE, Wang C, Berlin JM, Spicer TP, Fernandez-Vega V, Chase P, Hodder PS, Schűrer, **Nomura DK**, Rosen H, Fu GC, Cravatt BF. (2011) Academic cross-fertilization by

public screening yields a remarkable class of protein phosphatase methylesterase-1 inhibitors. *Proceedings of the National Academy of Sciences*, *USA* 108, 6811-6816. PMID: 21398589

178. Kopp F, Komatsu T, **Nomura DK**, Trauger SA, Thomas JR, Simon GM, Cravatt BF. (2010) The glycerophospho-metabolome and its influence on amino acid homeostasis by brain metabolomics of GDE1(-/-) mice. *Chemistry & Biology* 17, 831-840. PMID: 20797612

179. Schlosburg JE, Blankman JL, Long JZ, **Nomura DK**, Nguyen PT, Ramesh D, Kinsey SG, Booker L, Burston JK, Wise LE, Ghosh S, Selley DE, Sim-Selley LJ, Liu Q, Cravatt BF, Lichtman AH. (2010) Sustained inactivation of monoacylglycerol lipase produces functional antagonism of the brain endocannabinoid system. *Nature Neuroscience* 13, 1113-1119. PMID: 20729846

180. **Nomura DK**, Dix MM, Cravatt BF. (2010) Chemoproteomic Approaches for Biochemical Pathway Discovery in Cancer. *Nature Reviews Cancer* 10, 630-638. PMID: 20703252

181. **Nomura DK**, Long JZ, Niessen S, Hoover HS, Ng S-W, Cravatt BF. (2010) Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. *Cell* 140, 49-61. PMID: 20079333

182. Long JZ, **Nomura DK,** Vann RE, Walentiny DM, Booker L, Jin X, Burston JJ, Sim-Selley LJ, Lichtman AH, Wiley JL, Cravatt BF. (2009) Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. *Proceedings of the National Academy of Sciences, USA* 106*,* 20270-20275. PMID: 19918051

183. Long JZ, **Nomura DK**, Cravatt BF. (2009) Mechanistic characterization of selective monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. *Chemistry & Biology* 16, 744-753. PMID: 19635411

184. Ruby M*, **Nomura DK***, Hudak CS, Mangravite LM, Chiu S, Casida JE, Krauss RM. (2008) Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins. *Proceedings of the National Academy of Sciences, USA* 105, 14561-14566. PMID: 18794527 (* co-first author)

185. **Nomura DK**, Ward AM, Hudak CS, Burston JJ, Issa RS, Fisher KJ, Abood ME, Wiley JL, Lichtman A, Casida JE. (2008) Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. *Bioorganic Medicinal Chemistry Letters* 18, 5875-5878. PMID: 18752948

186. Casida JE, **Nomura DK**, Vose SC, Fujioka K. (2008) Organophosphate-Sensitive Lipases Modulate Brain Lysophospholipids, Ether Lipids and Endocannabinoids. *Chemico-Biological Interactions* 175, 355-64. PMID: 18495101

187. **Nomura DK**, Blankman JL, Simon GM, Fujioka K, Issa RS, Ward AM, Cravatt BF, Casida JE. (2008) Activation of the endocannabinoid system by organophosphorus nerve agents. *Nature Chemical Biology* 4, 373-378. PMID: 18438404

188. **Nomura DK**, Fujioka K, Issa RS, Ward AM, Cravatt BF, Casida JE. (2008) Dual Roles of Brain Serine Hydrolase KIAA1363 in Ether Lipid Metabolism and Organophosphate Detoxification. *Toxicology and Applied Pharmacology 228,* 42-482. PMID: 18154358

189. **Nomura DK**, Durkin KA, Chiang KP, Quistad GB, Cravatt BF, Casida JE. (2006) Serine Hydrolase KIAA1363: Toxicological and Structural Features with Emphasis on Organophosphate Interactions. *Chemical Research in Toxicology* 19, 1142-1150. PMID: 16978018

190. Quistad GB, Liang SN, Fisher KJ, **Nomura DK**, Casida JE. (2006) Each Lipase has a Unique Sensitivity Profile for Organophosphorus Inhibitors. *Toxicological Sciences* 91,166-172. PMID: 16449251

191. **Nomura DK**, Leung D, Chiang KP, Quistad GB, Cravatt BF, Casida JE. (2005) A Brain Detoxifying Enzyme for Organophosphorus Nerve Poisons. *Proceedings of the National Academy of Sciences, USA* 102, 6195-6200. PMID: 15840715

192. Segall Y, Quistad GB, Sparks SE, **Nomura DK**, Casida JE. (2003) Toxicological and Structural Features of Organophosphorus and Organosulfur Cannabinoid CB1 Receptor Ligands. *Toxicological Sciences* 76, 131-137. PMID: 12944568

193. Segall Y, Quistad GB, **Nomura DK**, Casida JE. (2003) Arachidonylsulfonyl Derivatives as Cannabinoid CB1 Receptor and Fatty Acid Amide Hydrolase Inhibitors. *Bioorganic Medicinal Chemistry Letters* 13,3301-3303. PMID: 12951114

194. Quistad GB, **Nomura DK**, Sparks SE, Segall Y, Casida JE. (2002) Cannabinoid CB1 Receptor as a Target for Chlorpyrifos Oxon and Organophosphorus Pesticides. *Toxicology Letters* 135, 89-93. PMID: 12243867

195. Quistad GB, Sparks SE, Segall Y, **Nomura DK**, Casida JE. (2002) Selective Inhibitors of Fatty Acid Amide Hydrolase Relative to Neuropathy Target Esterase and Acetylcholinesterase: Toxicological Implications. *Toxicology and Applied Pharmacology* 179, 57-63. PMID: 11884237

Patents

1. **Nomura DK,** Nuttall TM, Maimone TJ. Covalent destabilizing degraders against transcription factor PAX8. Provisional patent application filed August 8th, 2026. Application 64/128,536.
2. **Nomura DK,** Stieger CE, Dovala D, Johannessen CM, McKenna JM, Schirle M. Compositions and methods for targeted transcriptional repression by induced proximity. Provisional patent application filed October 7th, 2025
3. **Nomura DK,** Maimone TJ, Rosen HT, Li K. Sulfinyl aziridines. Provisional application filed on Feb 17th, 2025.
4. **Nomura DK,** Lim M, Do Cong T. DCAF16-based covalent handle for rational design of monovalent degraders. Provisional application filed on January 21st, 2024.
5. **Nomura DK,** Gowans GA, Forte N. Covalent Degraders of Oncogenic Transcription Factors. Provisional application filed on October 25th, 2023.
6. Shao Q, **Nomura DK**. Covalent Molecular Glue Stabilizers and Platform. PCT/US22/51591. PCT conversion filed on December 1st, 2022.
7. McKenna J, **Nomura DK**, Toriki E, Papatzimas J, Dovala D, Hesse M, Nishikawa K. Molecular Glue Degrader Compounds and Uses Thereof. PCT/US23/35642. PCT conversion filed October 21, 2023.
8. **Nomura DK,** Henning NJ, Spradlin JN, Ward CC, McKenna JM, Schirle M, Tallarico JA, Hesse M, Dovala D. Deubiquitinase Targeting Chimeras and Related Methods. PCT/US2022/027120; WO2022232634A1.
9. Rape M, **Nomura DK**, Henning N, Manford A. FEM1B protein binding agents and uses thereof. PCT application; PCT/US2021/021347; WO2021183431A1.
10. **Nomura DK**, Cioffi A, Schirle M, Boike L, Tallarico JA, McKenna JM, Liu G. MYC inhibitors and uses thereof. Provisional patent application filed. Abandoned
11. **Nomura DK**, Zoncu R, Chung YSC, Shin H, Canham S. mTORC1 inhibitors for Activating autophagy. PCT/US2020/013158; WO2020146779A1.
12. **Nomura DK**, Roberts AM, Bateman LA, Miyamoto DK, Huffman TR, Ward CC. Compositions and methods for modulating UBA5. PCT/US2018/016649; WO2018144869A1.
13. **Nomura DK,** Zoncu R, Roberts AM, Cho, KF, Chung YSC, Shin J, Croze B. mTORC1 modulators; Patent US20190112268A1.
14. **Nomura DK**, Zoncu R, Ward C, Fung SK, Varma CK, Fontaine B. Methods and compounds for targeted autophagy. Patent US20190290778A1.
15. Spradlin J, Ward CC, **Nomura DK,** Schirle M, Tallarico JA, McKenna JM, Maimone TJ, Hu X. Covalent targeting of E3 ligases. Patent US20210369731A1.
16. **Nomura DK,** Anderson KE. Thioredoxin modulators and uses thereof. PCT/US2018/024134; WO2018175958A1.
17. **Nomura DK**, Roberts LS, Ward CC. Compositions for treating breast cancer. PCT/US2018/017702; WO2018148598A1.
18. **Nomura DK,** Grossman EA, Ward CC, Bateman LA, Huffman TR, Miyamoto DK, Spradlin JL. Compositions and methods for modulating ppp2r1a. Patent US20200054651A1.
19. **Nomura DK,** Olzmann JA, Bateman LA, Nguyen TB, Miyamoto DK, Huffman TR, Roberts AM. Compositions and methods for inhibiting Reticulon 4. Patent US20200062696A1.
20. Bachovchin D, Chang JW, Cravatt BF, Li W, Moellering RE, **Nomura DK**. Anti-cancer serine hydrolase inhibitory carbamates. Patent US9249128B2.
21. Cravatt BF, Long JZ, Li W, **Nomura DK**. Methods and Compositions Related to Targeting Monoacylglycerol Lipase. Patent US8772318B2.

Abstracts/meetings/invited talks

1. Distinguished Guest Lecturer: **Nomura DK** (2026) Reimagining Druggability using Chemoproteomic Platforms. UNC Chapel Hill 5th Annual Chemical Biology Interface Symposium, Chapel Hill, North Carolina.
2. Invited Speaker: **Nomura DK** (2026) Reimagining Druggability using Chemoproteomic Platforms. Seminar Speaker at UT Southwestern, Dallas, Texas.
3. Invited Speaker: **Nomura DK** (2026) Reimagining Druggability using Chemoproteomic Platforms. Seminar Speaker at University of Virginia, Charlottesville, Virginia.
4. Invited Speaker: **Nomura DK** (2026) Reimagining Druggability using Chemoproteomic Platforms. Seminar Speaker at Boehringer Ingelheim, Vienna, Austria.
5. Keynote Speaker: **Nomura DK** (2026) Reimagining Druggability using Chemoproteomic Platforms. EFMC International Symposium on Medicinal Chemistry, Basel, Switzerland.
6. Invited Speaker: **Nomura DK** (2026) Reimagining Druggability using Chemoproteomic Platforms. Seminar Speaker at GSK, Collegeville, Pennsylvania.
7. Invited Speaker: **Nomura DK** (2026) Reimagining Druggability using Chemoproteomic Platforms. 2026 Molecular Therapeutics Initiative-Proxidrugs Meeting, Cres, Croatia.
8. Invited Speaker: **Nomura DK** (2026) Reimagining Druggability using Chemoproteomic Platforms. 2026 Molecular Therapeutics Biotech Day, UC Berkeley, Berkeley, CA.
9. Invited Speaker: **Nomura DK** (2026) Reimagining Druggability using Chemoproteomic Platforms. 2026 Innovative Genomics Institute seminar series, UC Berkeley, Berkeley, CA.
10. Invited Speaker: **Nomura DK** (2026) Reimagining Druggability using Chemoproteomic Platforms. 2026 Induced Proximity Modalities and Therapeutics Gordon Research Conference, Lewiston, ME.
11. Invited Speaker: **Nomura DK** (2026) Reimagining Druggability using Chemoproteomic Platforms. 2026 Aspen Cancer Conference, Aspen, Colorado.
12. Invited Speaker: **Nomura DK** (2026) Reimagining Druggability using Chemoproteomic Platforms. ACS National Medicinal Chemistry Symposium, Atlanta, Georgia.
13. Invited Speaker: **Nomura DK** (2026) Reimagining Druggability using Chemoproteomic Platforms. 2nd International Symposium on Chemical and Biomedical Imaging, Hong Kong.
14. Invited Speaker: **Nomura DK** (2026) Reimagining Druggability using Chemoproteomic Platforms. AACR Annual Meeting, San Diego, CA.
15. Invited Speaker: **Nomura DK** (2026) Reimagining Druggability using Chemoproteomic Platforms. Therapeutic Frontiers in Medicine: Mechanisms and Modalities Conference, Frankfurt, Germany
16. Invited Speaker: **Nomura DK** (2026) Reimagining Druggability using Chemoproteomic Platforms. Kyoto University Institute for Integrated Cell-Material Sciences Seminar Series, Kyoto, Japan
17. Invited Speaker: **Nomura DK** (2026) Reimagining Druggability using Chemoproteomic Platforms. Joint Seminar at Sanford Burnham Prebys Medical Discovery Institute and Scripps Research, La Jolla, CA.
18. Invited Speaker: **Nomura DK** (2026) Reimagining Druggability using Chemoproteomic Platforms. Proximity Based Biology and Therapeutics: Targeted Protein Degradation and Beyond, Keystone Symposia, Banff, Canada
19. Invited Speaker: **Nomura DK** (2026) Reimagining Druggability using Chemoproteomic Platforms. University of Utah, Department of Medicinal Chemistry, Salt Lake City, Utah.
20. Invited Speaker: **Nomura DK** (2026) Reimagining Druggability using Chemoproteomic Platforms. AACR Special Conference on Fusion Positive Cancers, Philadelphia, Pennsylvania.
21. Invited Speaker: **Nomura DK** (2026) Reimagining Druggability using Chemoproteomic Platforms. AACR Special Conference on Fusion Positive Cancers, Philadelphia, Pennsylvania.
22. Invited Speaker: **Nomura DK** (2025) Reimagining Druggability using Chemoproteomic Platforms. Covalent Drug Discovery Summit, Boston, Massachusetts.
23. Invited Speaker: **Nomura DK** (2025) Reimagining Druggability using Chemoproteomic Platforms. Max Planck Institute at Dortmund, Germany.
24. Keynote Speaker: **Nomura DK** (2025) Reimagining Druggability using Chemoproteomic Platforms. CeMM Ph.D. Symposium, Vienna, Austria.
25. Keynote Speaker: **Nomura DK** (2025) Reimagining Druggability using Chemoproteomic Platforms. Academic Drug Discovery Consortium. St Louis, MO.
26. Invited Speaker: **Nomura DK** (2025) Reimagining Druggability using Chemoproteomic Platforms. Stanford University Chemical Biology Seminar Series, Palo Alto, California.
27. Invited Virtual Speaker: **Nomura DK** (2025) Reimagining Druggability using Chemoproteomic Platforms. Monash University, Melbourne, Australia.

28. Keynote Speaker: **Nomura DK** (2025) Reimagining Druggability using Chemoproteomic Platforms. 14th Annual Conference of International Chemical Biology Society & 9th European Chemical Biology Symposium, Paris, France
29. Keynote Speaker: **Nomura DK** (2025) Reimagining Druggability using Chemoproteomic Platforms. Boston Discovery On-Target Conference, Boston, MA.
30. Keynote Speaker: **Nomura DK** (2025) Reimagining Druggability using Chemoproteomic Platforms. Promega Kornberg Innovation Seminar, Madison, WI.
31. Keynote Speaker: **Nomura DK** (2025) Reimagining Druggability using Chemoproteomic Platforms. Promega Targeted Protein Degradation and Induced Proximity Symposium, Madison, WI.
32. Invited Speaker: **Nomura DK** (2025) Reimagining Druggability using Chemoproteomic Platforms. ACS meeting, Washington DC.
33. Invited Speaker: **Nomura DK** (2025) Reimagining Druggability using Chemoproteomic Platforms. Astrazeneca, Boston, MA.
34. Invited Speaker: **Nomura DK** (2025) Reimagining Druggability using Chemoproteomic Platforms. Bioorganic Chemistry Gordon Research Conference, Andover, NH.
35. Invited Speaker: **Nomura DK** (2025) Reimagining Druggability using Chemoproteomic Platforms. 2nd Annual Chromatin Summit at Foghorn Therapeutics.
36. Invited Speaker: **Nomura DK** (2025) Reimagining Druggability using Chemoproteomic Platforms. AACR Annual Meeting, Chicago, IL.
37. Invited Speaker: **Nomura DK** (2025) Reimagining Druggability using Chemoproteomic Platforms. Drug Discovery Chemistry Conference, San Diego, CA.
38. Invited Speaker: **Nomura DK** (2025) Reimagining Druggability using Chemoproteomic Platforms. Incyte Pharmaceuticals, Philadelphia, Pennsylvania.
39. Invited Speaker: **Nomura DK** (2025) Reimagining Druggability using Chemoproteomic Platforms. The Mark Foundation for Cancer Research Symposium, New York City, NY.
40. Invited Speaker: **Nomura DK** (2025) Reimagining Druggability using Chemoproteomic Platforms. 4th Frankfurt Conference on Quality Control of Life Processes, Frankfurt, Germany.
41. Invited Speaker: **Nomura DK** (2025) Reimagining Druggability using Chemoproteomic Platforms. 130th International Titisee Conference—Stress signaling in development and disease, Titisee, Germany.
42. Invited Speaker: **Nomura DK** (2025) Reimagining Druggability using Chemoproteomic Platforms. MIT, Department of Bioengineering, Cambridge, MA.
43. Invited Speaker: **Nomura DK** (2025) Reimagining Druggability using Chemoproteomic Platforms. ETH Zurich, Department of Chemistry, Zurich, Switzerland.
44. Invited Speaker: **Nomura DK** (2025) Reimagining Druggability using Chemoproteomic Platforms. Induced Proximity Keystone Conference, Santa Fe, New Mexico.
45. Invited Speaker: **Nomura DK** (2025) Reimagining Druggability using Chemoproteomic Platforms. Yale University, Department of Chemistry, New Haven, CT.
46. Invited Speaker: **Nomura DK** (2025) Reimagining Druggability using Chemoproteomic Platforms. University of Chicago Department of Cancer Biology, Chicago, IL.
47. Behringer Simon Academic Lecture: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. Emergency of irreversible modulation in drug discovery, ETH Zurich, Zurich, Switzerland.
48. Invited Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. Genentech, Department of Process and Discovery Chemistry, South San Francisco, CA.
49. Invited Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. Bay Area Chemical Biology Symposium at Stanford University.
50. Invited Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. Emergency of irreversible modulation in drug discovery, Astrazeneca/British Pharmacological Society, Cambridge, UK.
51. Invited Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. Inaugural Skaggs Therapeutics seminar series, UCSD, La Jolla, CA.
52. Invited Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. UC Drug Discovery Center Symposium, UCLA, Los Angeles, CA.
53. Invited Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. American Chemical Society meeting, Denver, CO.
54. Invited Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. ASCO Meeting, Yokohama, Japan.

55. Keynote Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. Vanderbilt Institute of Chemical Biology Symposium, Nashville, TN.
56. Keynote Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. Global Neurofibramatosis Meeting, Brussels, Belgium.
57. Invited Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. FASEB Ubiquitin meeting, Niagara Falls, NY.
58. Invited Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. Société de Chimie Thérapeutique (SCT) "TPD one-day symposium", Paris, France.
59. Invited Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. University of Oxford, Oxford, UK.
60. Invited Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. Protein Degradation in Focus: Symposium 2024 in Dundee, Dundee, UK.
61. Invited Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. University of Washington, Seattle, Department of Chemistry Seminar Series, Seattle, WA.
62. Plenary Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. 61st Annual MIKIW Meeting-in-Miniature, Chicago, IL.
63. Kenneth J. Klabunde Memorial Lecture: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. Kansas State University, Manhattan, KS.
64. Chair and Invited Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. American Association for Cancer Research Annual Meeting, San Diego, CA
65. Plenary Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. 19th Annual Drug Discovery Chemistry, San Diego, CA
66. Invited Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. "Frontiers in Medicinal Chemistry 2024" Conference organized by the German Chemical Society (GDCh) and the German Pharmaceutical Society (DPhG), Munich, Germany.
67. Hamilton Lecture Invited Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. Temple University, Philadelphia, Pennsylvania.
68. Invited Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. National Cancer Institute seminar series, Maryland.
69. Invited Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. Society for Laboratory Automation and Screening meeting, Boston, Massachusetts.
70. Invited Speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. Targeted Protein Degradation and Induced Proximity Keystone meeting, Keystone, Colorado.
71. Invited speaker: **Nomura DK** (2024) Reimagining Druggability using Chemoproteomic Platforms. Beth Israel Deaconess Medical Center Cancer Research Institute seminar series, Boston, Massachusetts.
72. Plenary Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. 13th International Symposium on Bioorganic Chemistry, Singapore.
73. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Ubiquitin Biology and Disease Keystone Meeting, Keystone, Colorado.
74. Keynote Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Chemistry at the Interface of Biology and Medicine Symposium, Columbia University, New York, New York.
75. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, Massachusetts.
76. Keynote Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. 2023 45th Princeton ACS Fall Organic Chemistry Symposium, Princeton, New Jersey.
77. Keynote Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. 2023 Purdue University Drug Discovery symposium, West Lafayette, Indianna.
78. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Leiden University Department of Chemistry, Leiden, Netherlands.
79. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Technical University of Munich Department of Chemistry, Munich, Germany.
80. Invited Speaker: **Nomura DK** (2023) Using Covalency to Enable Drug Discovery. Novartis Institutes for BioMedical Research, Basel, Switzerland.
81. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. 2023 Induced Proximity Drug Discovery Summit, Boston, Massachusetts.

82. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. 2023 Activity-Based Protein Profiling Meeting, Tel Aviv, Israel.
83. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Boston University's Center for Molecular Discovery 2023 Symposium, Boston, MA.
84. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Proximity-inducing pharmacology: Targeted protein degradation and beyond meeting, IRB Barcelona, Barcelona, Spain.
85. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Massachusetts General Hospital Cancer Center Seminar Series, Boston, MA.
86. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Special Seminar at Pfizer, Groton, CT.
87. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. 5th Annual Symposium on Applied Synthesis, Connecticut College, CT.
88. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Novalix Conference on Biophysics in Drug Discovery, Philadelphia, Pennsylvania.
89. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. University of Florida Scripps Symposium, Jupiter, Florida.
90. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. AACR meeting in Orlando, Florida.
91. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Cambridge Healthtech Drug Discovery Chemistry conference, San Diego, CA
92. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Cambridge Healthtech Drug Discovery Chemistry conference, San Diego, CA
93. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Yale University, Department of Molecular, Cellular, and Developmental Biology Seminar Series, New Haven, CT.
94. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Third Rock Ventures Covalent Drug Discovery Symposium, Boston, MA
95. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Dana Farber Cancer Center, Targeted Protein Degradation Seminar Series, Boston, MA.
96. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Kisaco Targeted Degradation and Undruggables Summit, Boston, MA.
97. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Baylor College of Medicine, Houston, TX.
98. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Japan Chemical Biology meeting, Osaka, Japan.
99. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Princeton University Department of Chemistry seminar series, Princeton, NJ.
100. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Hanson Wade Molecular Glue Degrader Summit, Boston, MA.
101. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Harvard Medical School Department of Cell Biology student invite, Boston, MA.
102. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. University of Illinois, Urbana Champagne, 18th Annual CBI TP Symposium for the Chemistry-Biology Interface Training Program (CBITP), Urbana-Champagne, Illinois.
103. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. FASEB Ubiquitin and Ubiquitin-like proteins conference, Boston, MA.
104. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. Applied Pharmaceutical Chemistry Symposium, Cambridge, MA.
105. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. 2nd Metabolism in Health and Disease, Cancun, Mexico.
106. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. 2nd Induced Proximity-Based Drug Discovery Summit, Boston, MA.
107. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. American Association of Cancer Research meeting, New Orleans, LA.

108. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. UC Santa Cruz Department of Chemistry seminar series, Santa Cruz, CA.
109. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. RSC Fragment based drug discovery, Cambridge, UK.
110. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. University of Pennsylvania, Department of Chemistry, Virtual.
111. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. Induced Proximity Targeting and Undruggables Conference, Boston, MA.
112. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. Johns Hopkins University, Chemical Biology Interface Program student invite, Baltimore, Maryland.
113. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Pacific Chem Conference, Virtual.
114. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. NYAS Targeted Protein Degradation: From Drug Discovery to the Clinic, Virtual
115. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Research seminar at Emory University, Atlanta, GA.
116. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Research seminar at University of Southern California, Los Angeles, CA.
117. Keynote Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. International Chemical Biology Society meeting, Virtual
118. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. LMU Munich Organic Chemistry seminar, Virtual
119. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Research seminar at UC Irvine, Irvine, CA.
120. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Research seminar at University of Minnesota, Minneapolis, Minnesota.
121. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Discovery on Target meeting, Cambridge, MA
122. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Novartis: Frontiers of Science and Medicine Institutional Lecture, Cambridge, MA
123. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Dana Farber Cancer Institute Chemical Biology Symposium, Virtual
124. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. European Targeted Protein Degradation meeting, Virtual
125. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Vertex research seminar, Boston, MA
126. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Induced Proximity-Based Drug Discovery Summit, Hanson Wade, Virtual.
127. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. BioTechne Symposium: Advances in Targeted Protein Degradation, Virtual
128. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Ligase Targeting Drug Development, Hanson Wade, Virtual.
129. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. AACR meeting Chemistry in Cancer Research Town Hall, Virtual
130. Invited Speaker: **Nomura DK** (2021) Developing Coronavirus Anti-Viral Drugs. Center for Emerging and Neglected Diseases Symposium, Virtual.
131. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Helmholtz Drug Discovery Conference Speaker, Virtual.
132. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Rutgers University seminar speaker, Virtual.
133. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. North American Protein Degradation Congress meeting, Kisaco Research, Virtual.
134. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Targeted Protein Degradation & PROTAC symposium, Oxford Global, Virtual.
135. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Stanford University, Department of Chemistry, Virtual.

136. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. SLAS International Conference, Virtual.
137. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. UCSF Cancer Center, Virtual.
138. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. Dana Farber Cancer Center Targeted Protein Degradation Seminar Series, Virtual.
139. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. Janssen, Virtual.
140. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. Oregon Health Sciences University, Virtual.
141. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. 3rd Annual Targeted Protein Degradation Meeting, Virtual.
142. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. 18th Annual Discovery on Target Conference, Virtual.
143. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. Northwestern University Department of Chemistry, Virtual.
144. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. Pfizer, Virtual.
145. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. Transcription Factor Drug Development Conference, Virtual.
146. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. Seminar at Cygnal Therapeutics, Virtual.
147. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. Natural Products Symposium at the New York Academy of Sciences, Virtual.
148. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. North American Targeted Degradation Summit. San Diego, CA.
149. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. The Mark Foundation for Cancer Research Induced Proximity Meeting, New York, New York
150. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. MIT/Broad Institute Chemical Biology seminar series, Cambridge, MA
151. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Seminar at Calico, South San Francisco, CA
152. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. California Institute of Technology Chemical Biology seminar series, Pasadena, CA
153. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. UT San Antonio, San Antonio, TX.
154. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Harvard University Chemistry and Chemical Biology seminar speaker, Cambridge, MA
155. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Memorial Sloan Kettering Cancer Center, New York, NY.
156. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Bayer Life Science Workshop: Chemical Biology—Jointly Exploring New Frontiers, Berlin, Germany
157. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. 2nd Targeted Protein Degradation Summit meeting, Boston, MA
158. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Northwestern University, Chicago, IL.
159. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. American Chemical Society meeting, Targeted Protein Degradation session, San Diego, CA.
160. Invited Speaker**: Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Janssen Pharmaceuticals seminar speaker, Springhouse, Pennsylvania.
161. Invited Speaker**: Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Targeted Drug Discovery Summit, Boston, MA.
162. Invited Speaker**: Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. 60th International Conference on the Biosciences of Lipids, Tokyo, Japan.
163. Invited Speaker**: Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Bioorganic Chemistry Gordon Research Conference, Andover, NH.

164. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Novartis Institutes for BioMedical Research, Basel, Switzerland.
165. Invited Speaker**: Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. European Targeted Protein Degradation meeting, Basel, Switzerland
166. Invited Speaker**: Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Cayman Chemical Biology Symposium at the University of Michigan, Ann Arbor, Ann Arbor, MI.
167. Invited Speaker**: Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Yale Chemical Biology symposium, New Haven, CT.
168. Invited Speaker**: Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. World Molecular Engineering Network meeting, Cabo San Lucas, Mexico.
169. Invited Speaker**: Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. American Cancer Society meeting, Orlando, FL.
170. Invited Speaker**: Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Structural Genomics Consortium Targeted Protein Degradation meeting, Toronto, CA.
171. Invited Speaker**: Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Mark Foundation for Cancer Research Symposium, New York, NY.
172. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Medicinal and Bioorganic Chemistry Foundation meeting, Steamboat, CO.
173. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. 1st Targeted Protein Degradation Summit meeting, Boston, MA
174. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. Merck and Co. Organic Chemistry Seminar Series, Kenilworth, NJ.
175. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. Caltech Department of Chemistry, Pasadena, California.
176. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. EMBO Enzymes and Catalysis meeting, Pavia, Italy.
177. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. City of Hope Research Institute, Los Angeles, CA
178. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. Structural Genomics Consortium on Target 2035. Berlin, Germany
179. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. BASF Metanomics, Berlin, Germany
180. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. Pharmaron, Beijing, China.
181. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. BASF-CARA Symposium, Santa Barbara, CA.
182. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. Cambridge Healthtech Institute's 17th Annual World Preclinical Congress, Boston, MA.
183. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. ACS National Medicinal Chemistry Symposium, Nashville, TN.
184. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. Merck, South San Francisco, CA.
185. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. 2018 San Antonio Drug Discovery Symposium, San Antonio, TX.
186. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. AACR meeting, Chicago, IL.
187. Invited Speaker and Session Chair: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. ASBMB meeting, San Diego, CA.
188. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. Agios, Cambridge, MA.
189. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. Astrazeneca, Waltham, MA.
190. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. University of California, Riverside, Riverside, CA.
191. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. Tumor Metabolism Keystone meeting, Snowbird, Utah.

192. Invited Speaker: **Nomura DK** (2017) Redefining Toxicology and Druggability using Chemoproteomic Platforms. Superfund Research Program meeting, Philadelphia, Pennsylvania.
193. Invited Speaker: **Nomura DK** (2017) Redefining Druggability using Chemoproteomic Platforms. Tufts University Medical School, Boston, MA.
194. Invited Speaker: **Nomura DK** (2017) Redefining Druggability using Chemoproteomic Platforms. University of Virginia, Charlottesville, VA.
195. Invited Speaker and Wendell Griffith Lecturer: **Nomura DK** (2017) Redefining Druggability using Chemoproteomic Platforms. St Louis University, St. Louis, MO.
196. Invited Speaker: **Nomura DK** (2017) Redefining Druggability using Chemoproteomic Platforms. AACR Advances in Breast Cancer Meeting, Hollywood, CA.
197. Invited Speaker: **Nomura DK** (2017) Redefining Druggability using Chemoproteomic Platforms. Austrian Proteomics Association meeting, Graz, Austria.
198. Invited Speaker: **Nomura DK** (2017) Chemoproteomic Platforms for Mapping Druggable Hotspots in Disease. Enzymes, Coenzymes, & Metabolic Pathways Gordon Conference. Waterville Valley, NH.
199. Invited Speaker: **Nomura DK** (2017) Chemoproteomic and Metabolomic Platforms for Mapping Drivers of Disease. American Diabetes Association meeting. San Diego, CA.
200. Invited Speaker: **Nomura DK** (2017) Chemoproteomic Platforms for Mapping Druggable Hotspots in Disease. Royal Society of Chemistry Chemical Biology Symposium. London, UK.
201. Invited Speaker: **Nomura DK** (2017) Chemoproteomic Platforms for Mapping Druggable Hotspots in Disease. World Molecular Engineering Network conference, San Jose Del Cabo, Mexico.
202. Invited Speaker: **Nomura DK** (2017) Using Chemoproteomic and Metabolomic Platforms to Map Drivers of Human Disease, UCSF Breast Oncology Program Seminar, San Francisco, CA.
203. Invited Speaker: **Nomura DK** (2017) Using Chemoproteomic and Metabolomic Platforms to Map Drivers of Human Disease, Cold Spring Harbor Laboratory, Chemistry and Metabolism Symposium, Cold Spring Harbor, NY.
204. Invited Speaker: **Nomura DK** (2017) Using Chemoproteomic and Metabolomic Platforms to Map Drivers of Human Disease, Johns Hopkins Medical School, Department of Biological Chemistry, Baltimore, Maryland.
205. Invited Speaker: **Nomura DK** (2016) Using Chemoproteomic Platforms for Drug Discovery and Toxicology, The University of Syndey Charles Perkin Centre, Syndey, Australia.
206. Keynote Speaker: **Nomura DK** (2016) Using Chemoproteomic Platforms for Drug Discovery and Toxicology, Third Australian Lipids Meeting, Melbourne, Australia.
207. Invited Speaker: **Nomura DK** (2016) Using Chemoproteomic Platforms for Drug Discovery and Toxicology, University of Georgia, Athens, Georgia.
208. Invited Speaker: **Nomura DK** (2016) Using Chemoproteomic Platforms for Drug Discovery and Toxicology, UCSD Metabolomics Symposium, La Jolla, CA.
209. Invited Speaker: **Nomura DK** (2016) Using Chemoproteomic Platforms for Drug Discovery and Toxicology, Oregon Health State University, Portland, Oregon.
210. Invited Speaker: **Nomura DK** (2016) Using Chemoproteomic Platforms for Drug Discovery and Toxicology, Amgen South San Francisco, CA
211. Invited Speaker: **Nomura DK** (2016) Using Chemoproteomic Platforms for Drug Discovery and Toxicology, Vanderbilt University Chemical Biology Seminar Series, Nashville, Tenessee.
212. Invited Speaker: **Nomura DK** (2016) Using Chemoproteomic Platforms for Toxicology and Drug Discovery GETA (Genetic and Environmental Toxicology Association) Symposium, Oakland, CA.
213. Invited Speaker: **Nomura DK** (2016) Mapping Metabolic Drivers of Cancer using Chemoproteomic and Metabolomic Platforms. Gilead Medicinal Chemistry Seminar Series, Foster City, CA.
214. Invited Speaker: **Nomura DK** (2016) Mapping Metabolic Drivers of Cancer using Chemoproteomic and Metabolomic Platforms. Gordon Conference on Bioorganic Chemistry, New Hampshire.
215. Invited Speaker: **Nomura DK** (2016) Mapping Metabolic Drivers of Cancer using Chemoproteomic and Metabolomic Platforms. AACR National Meeting, New Orleans, Louisiana.
216. Invited Speaker: **Nomura DK** (2016) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. University of Pavia, Italy.
217. Invited Speaker: **Nomura DK** (2016) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. Medical University of Graz, Graz, Austria.

218. Invited Speaker: **Nomura DK** (2016) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. Keystone Science Lecture Speaker at National Institutes for Environmental Health Sciences, Research Triangle Park, North Carolina.
219. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. Cleveland Clinic, Cleveland, Ohio.
220. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. Purdue University, Department of Nutrition, Indiana.
221. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. UCLA, Los Angeles, California.
222. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. University of Wisconsin, Madison Department of Biochemistry, Madison, Wisconsin.
223. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. UCSF Cancer Center, San Francisco, CA
224. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. UCSF Endocrinology, San Francisco, CA
225. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. UCSD Bioengineering Department, La Jolla, CA
226. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. Dana Farber Cancer Institute, Boston, Massachusetts.
227. Invited Keynote Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Cancer using Chemoproteomic and Metabolomic Platforms. Molecular and Cell Biology of Lipids Gordon Conference, Waterville Valley, New Hampshire.
228. Poster Presenter: **Nomura DK** (2015) Mapping Metabolic Drivers of Cancer using Chemoproteomic and Metabolomic Platforms. High Throughput Chemistry and Chemical Biology Gordon Conference, New London, New Hampshire.
229. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Cancer using Chemoproteomic and Metabolomic Platforms. AACR Metabolism and Cancer meeting, Bellevue, Washington.
230. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. Lipid Maps Meeting 2015, La Jolla, CA.
231. Invited Speaker: **Nomura DK** (2015) Mapping Dysregulated Metabolic Pathways in Disease Using Chemoproteomic and Metabolomic Platforms, Dana Farber/Harvard Medical School, Boston, MA.
232. Invited Speaker: **Nomura DK** (2015) Mapping Dysregulated Metabolic Pathways in Disease Using Chemoproteomic and Metabolomic Platforms, Searle Meeting, Chicago, IL.
233. Invited Speaker: **Nomura DK** (2015) Mapping Dysregulated Metabolic Pathways in Disease Using Chemoproteomic and Metabolomic Platforms, University of Chicago, Chicago, IL.
234. Invited Speaker: **Nomura DK** (2015) Mapping Dysregulated Lipid Metabolism in Disease using Chemoproteomic and Metabolomic Platforms, RIKEN, Yokohama, Japan.
235. Invited Speaker: **Nomura DK** (2015) Mapping Dysregulated Lipid Metabolism in Disease using Chemoproteomic and Metabolomic Platforms, Phospholipase Meeting, Tokyo, Japan.
236. Seminar speaker: **Nomura DK** (2014) Chemoproteomic and Metabolomic Strategies for Drug Discovery and Toxicology, UC Berkeley, Nutritional Sciences and Toxicology Department
237. Poster/Talk: **Nomura DK** (2014) Mapping Dysregulated Metabolic Pathways in Cancer Using Functional Proteomic and Metabolomic Platforms, Gordon Conference, Coenzymes, and Metabolic Pathways, Waterville Valley, NH.
238. Invited Speaker: **Nomura DK** (2014) Chemoproteomic and Metabolomic Strategies for Drug Discovery and Toxicology, Genentech, South San Francisco, CA Investigative Toxicology Division
239. Poster: **Nomura DK** (2014) Mapping Dysregulated Metabolic Pathways in Cancer Using Functional Proteomic and Metabolomic Platforms, Searle Scholars Meeting, Chicago, IL.
240. Invited Speaker: **Nomura DK** (2014) Mapping Dysregulated Lipid Metabolism in Cancer using Chemoproteomic and Metabolomic Platforms, ASBMB meeting, San Diego, CA.
241. Invited Speaker: **Nomura DK** (2014) Mapping Dysregulated Lipid Metabolism in Cancer using Chemoproteomic and Metabolomic Platforms, Keystone Meeting on Tumor Metabolism, Whistler, Canada.
242. Invited Speaker: **Nomura DK** (2014) Validating Monoacylglycerol Lipase Inhibitors in Combatting Parkinson's Disease, Michael J Fox Foundation, New York, NY.

243. Invited Seminar Speaker: **Nomura DK** (2014) Mapping Dysregulated Metabolic Pathways in Disease using Chemoproteomic and Metabolomic Platforms, Karolinska Institute, Stockholm, Sweden.
244. Invited Seminar Speaker: **Nomura DK** (2014) Mapping Dysregulated Metabolic Pathways in Disease using Chemoproteomic and Metabolomic Platforms, University of Pavia, Pavia, Italy.
245. Invited Seminar Speaker: **Nomura DK** (2013) Mapping Dysregulated Metabolic Pathways in Disease using Chemoproteomic and Metabolomic Platforms, Novartis, Cambridge, MA.
246. Invited Seminar Speaker: **Nomura DK** (2013) Mapping Dysregulated Metabolic Pathways in Disease using Chemoproteomic and Metabolomic Platforms, UC Merced, Merced, CA.
247. Invited Speaker: **Nomura DK** (2013) Endocannabinoid hydrolysis generates eicosanoids that promote inflammation. Bioactive Lipids in Cancer, Inflammation, and Related Diseases meeting, San Juan, Puerto Rico—received Eicosanoids Research Foundation Young Investigator Award.
248. Keynote Speaker: **Nomura DK** (2013) Chemoproteomic and Metabolomic Strategies for Drug Discovery and Toxicology. NorCal Society of Toxicology meeting, South San Francisco, CA.
249. Invited Speaker: **Nomura DK** (2013) Mapping dysregulated metabolic pathways in disease using functional proteomic and metabolomic platforms. Symposium on Frontier Sciences on New Drug Discovery, Tsinghua University, Beijing, China.
250. Invited Speaker: **Nomura DK** (2013) Mapping dysregulated metabolic pathways in disease using functional proteomic and metabolomic platforms. Transatlantic Frontiers of Chemistry (TFOC) meeting, American Chemical Society, Kloster Seon, Germany.
251. Invited Speaker: **Nomura DK** (2013) Endocannabinoid hydrolysis generates eicosanoids that promote inflammation. Gordon conference Molecular and Cellular Biology of Lipids, New Hampshire, NJ
252. Poster: **Nomura DK** (2013) Mapping dysregulated metabolic pathways in cancer. Gordon conference bioorganic chemistry, New Hampshire, NJ.
253. Poster: **Nomura DK** (2013) Mapping Dysregulated Metabolic Pathways in Cancer Using Functional Proteomic and Metabolomic Platforms, Searle Scholars Meeting, Chicago, IL.
254. Invited Speaker: **Nomura DK** (2013) Mapping Dysregulated Metabolic Pathways in Disease using Functional Proteomic and Metabolomic Platforms. Seminar speaker at UC Berkeley, Department of Molecular and Cell Biology, Berkeley, CA
255. Invited Speaker: **Nomura DK** (2013) Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Seminar speaker at University of Minnesota, Minneapolis, MN.
256. Invited Speaker: **Nomura DK** (2012) Mapping dysregulated metabolic pathways in disease using functional proteomic and metabolomic platforms. Seminar speaker at Agilent, Santa Clara, CA.
257. Invited Speaker: **Nomura DK** (2012) Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Seminar speaker at Pfizer Neuroscience, Cambridge, MA.
258. Invited Speaker: **Nomura DK** (2012) Mapping Dysregulated Metabolic Pathways using Functional Chemoproteomic and Metabolomic Platforms. Seminar Speaker at Children's Hospital Oakland Research Institute, Oakland, CA.
259. Keynote Invited Speaker: **Nomura DK** (2012) Mapping dysregulated metabolic pathways in cancer using functional proteomic and metabolomic platforms. Austrian Proteomics Research Symposium, Graz, Austria.
260. Invited Speaker: **Nomura DK**. (2012) Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. *International Cannabinoid Research Society* meeting, Freiberg, Germany.
261. Poster: **Nomura DK** and Samad TA (2012) Metabolomic profiling for mapping anti-inflammatory pathways in neurodegenerative disease. *Genetics and Chemistry Cell Symposium,* Cambridge, Massachusetts.
262. Invited Speaker: **Nomura DK** (2012) Endocannabinoid hydrolysis generates brain eicosanoids that promote neuroinflammation. *SciCafe* hosted by Nature Biotechnology and Nature Medicine at the Gladstone Institute, San Francisco, CA
263. Poster: **Nomura DK** and Cravatt BF (2011) Monoacylglycerol Lipase Exerts Bidirectional Control over Endocannabinoid and Fatty Acid Pathways to Support Prostate Cancer. Cancer Chemical Biology meeting sponsored by Nature Chemical Biology, Cambridge, Massachusetts.
264. Invited Speaker: **Nomura DK** (2011) Mapping dysregulated metabolic pathways in cancer using activity-based proteomics. American Chemical Society meeting, Denver, Colorado.
265. Invited Speaker: **Nomura DK,** Cravatt BF (2011) Mapping dysregulated metabolic pathways in cancer. American Association for Cancer Research meeting, Orlando, Florida.

266. Invited Speaker: **Nomura DK**, Long JZ, Cravatt BF, Casida JE. (2010) Annotating the role of monoacylglycerol lipase in cancer and in the brain. American Chemical Society meeting, San Francisco, California.
267. Invited Speaker: **Nomura DK**. (2009) Chemical Approaches to Annotating Toxicological and Biological Systems. University of California Toxic Substances & Teaching Program Symposium, Berkeley, California.
268. Poster: **Nomura DK**, Blankman JL, Simon GM, Cravatt BF, Casida JE. (2008) Maximal activation of the endocannabinoid system by organophosphorus nerve agents. University of California Toxic Substances Research & Teaching Program Symposium, Riverside, California.
269. Poster: **Nomura DK**, Casida JE. (2007) Acetyl monoalkylglycerol ether deacetylase: an organophosphate detoxifying enzyme and modulator of tumor growth. IXth Meeting on Cholinesterases, Souzhou, China.
270. Oral Presentation: **Nomura DK**, Durkin KA, Chiang KP, Quistad GB, Cravatt BF, Casida JE. (2006) Toxicological and Structural Features of KIAA1363: A Novel Detoxifying Enzyme for Organophosphorus Nerve Poisons. American Chemical Society meeting, San Francisco, CA.
271. Poster: **Nomura DK**, Leung D, Chiang KP, Quistad GB, Cravatt BF, Casida JE. (2005) A Brain Detoxifying Enzyme for Organophosphorus Nerve Poisons. American Chemical Society meeting, Washington, D.C.

Students/Researchers Supervised (w/ former and current position)

Name	Position in the lab	Current Position
Daphne Huang (2026-current)	Undergraduate Researcher	
Kazushi Suzuki (2026-current)	Kyoto Program-Specific Assistant Professor	
Biswajit Roy (2026-current)	Kyoto Postdoctoral Fellow	
Natasha Gupta (2026-current)	Undergraduate Researcher	
Lilly Kawabata (2026-current)	Undergraduate Researcher	
Haley Chan (2026-current)	Undergraduate Researcher	
Emily White (2026-current)	Undergraduate Researcher	
Abigaile Hwang (2026-current)	Undergraduate Researcher	
Taijia Liang (2026-current)	Undergraduate Researcher	
Mihira Gutti (2025-current)	Undergraduate Researcher	
Haley van Meurs (2025-2026)	Undergraduate Researcher	
Justin Wang (2025-current)	Undergraduate Researcher	
Timothy Truong (2025-2025)	Undergraduate Researcher	
Zhenyao Sun (2025-2025)	Undergraduate Researcher	
Melody Guo (2025-current)	Postdoctoral Fellow	
Sheena Garcia (2025-current)	Postdoctoral Fellow	
Nicholas Foster (2025-current)	Undergraduate Researcher	
Calise Solla (2025-current)	Graduate Student	
Phillip Kim (2025-current)	Graduate Student	
Isaac Joyner (2025-current)	Postdoctoral Fellow	
Derek Tran (2025-current)	Postdoctoral Fellow	
Catherine Tran (2024-current)	Undergraduate Researcher	
Dushanti Patterson (2024-2025)	Undergraduate Researcher	
Andie Chen (2024-2026)	Undergraduate Researcher	PhD program at Yale
Emily Lau (2024-current)	Undergraduate Researcher	
Maia Caldwell (2024-2024)	Undergraduate Researcher	
Harrison Chang (2024-2025)	Undergraduate Researcher	
Suh Hyun (Celina) Lee (2024-2026)	Undergraduate Researcher	Research Associate at Biotium
Grace Zhou (2024-2025)	Undergraduate Researcher	
Edward Pandji (2024-2025)	Undergraduate Researcher	PhD program at Northwestern Univ.
Vincent DeMarco (2024-2026)	Undergraduate Researcher	PhD program at U Michigan
Yun Hu (2024-current)	Postdoctoral Fellow	
John Gao Dong (2024-2025)	Undergraduate Researcher	
Alyssa Chew (2024-2025)	Undergraduate Researcher	

Yihan Lin (2024-2025)	Undergraduate Researcher	PhD program at CalTech
Kosuke Chiba (2024-current)	Postdoctoral Fellow	
Christine Vo (2023-2025)	Undergraduate Researcher	
Anna Chen (2023-2024)	Undergraduate Researcher	
Jon Giller (2023-2025)	Undergraduate Researcher	PhD program at Yale University
Elijah Lee (2023-2026)	Undergraduate Researcher	PhD program at Scripps Research
Claire Song (2023-2025)	Undergraduate Researcher	
Amy Tsao (2023-2025)	Undergraduate Researcher	
Christian Stieger (2024-current)	Postdoctoral Fellow	
Kohei Toh (2023-2024)	Postdoctoral Fellow	Scientist at Sumitomo Pharma
Carolyn Glasser (2023-current)	Graduate Student	
Alicia (Flor) Gowans (2023-2024)	Postdoctoral Fellow	Senior Scientist at Genentech
Zoe Duong (2023-current)	Graduate Student	
Inji Park (2023-2024)	Undergraduate Researcher	PhD program at Princeton University
Alicia Zhang (2023-2025)	Undergraduate Researcher	PhD program at UC Berkeley
Tasha Tanabe (2023-current)	Undergraduate Researcher	
Kohei Toh (2023-2024)	Postdoctoral Fellow	Scientist at Sumitomo Pharma
Erica Quitales (2023-current)	Postdoctoral Fellow	
Thang Docong (2023-current)	Postdoctoral Fellow	
Brynne Currier (2023-2025)	Undergraduate Researcher	Research tech at Stanford in Ting lab
Aman Modi (2022-2026)	Graduate Student	
Justin Hatcher (2022-2024)	Undergraduate Researcher	
Taylor Nuttall (2022-current)	Graduate Student	
Lily Garelick (2022-2022)	Undergraduate Researcher	
Yuki Terauchi (2022-2023)	Visiting Scholar	Scientist at Otsuka Pharma
Melissa Lim (2022-2026)	Graduate Student	Scientist at Astrazeneca
Hannah Rosen (2022-2026)	Graduate Student	Postdoc at Exir Bio
Seong Ho (Johnny) Hong (2022-2023)	Postdoctoral Fellow	Scientist at Stealth startup
Hannah Grupe (2022-2023)	Research Technician	PhD program at Stanford University
Nathan Hsu (2022-2025)	Undergraduate Researcher	
Zoe Duong (2022-2023)	Undergraduate Researcher	PhD program at UC Berkeley
Melissa Pighetti (2021-2022)	Oxford University Exchange Student	PhD program at Princeton University
Lauren Orr (2021-2025)	Graduate Student	Scientist at Octant
Emily Ho (2021-2025)	Undergraduate Researcher	PhD program at UCSF
Halime Yilmaz (2021-2024)	Undergraduate Researcher	PhD program at UCLA
Amy Cho (2021-2023)	Undergraduate Researcher	PhD program at Stanford University
Kaila Nishikawa (2021-2023)	Undergraduate Researcher	PhD program at Tri-I PhD program
Anand Divakaran (2021-2024)	Postdoctoral Fellow	Scientist at Vicinitas Therapeutics
Xavier Tao (2021-2023)	Undergraduate Researcher	PhD program at Harvard University
Belen E. Altamirano Poblano (2021-2023)	Undergraduate Researcher	Research Technician at UCSF
Sabine Cismoski (2021-2024)	Undergraduate Researcher	PhD program at UCSF
Katelyn Randal (2021-2022)	Undergraduate Researcher	PhD program at Stanford University
Anoohya Panidapu (2021-2023)	Undergraduate Researcher	Clinical Coordinator at Stanford
Vienna Thomas (2020-2025)	Graduate Student	Intern at Flagship Pioneering
Ethan Toriki (2020-2024)	Graduate Student	Novartis Postdoctoral Fellow
Margot Meyers (2020-2024)	Graduate Student	Scientist at Interdict Bio
Abigail Estes (2020-2021)	Graduate Student	Scientist at Merck
Elizabeth King (2020-2025)	Graduate Student	Senior Scientist at Astrazeneca
Nafsika Forte (2020-2023)	Postdoctoral Fellow	Scientist at Vicinitas Therapeutics
James Papatzimas (2020-2023)	Postdoctoral Fellow	Medical Science Liaison at Novo
Matthew Cerda (2020-2021)	Postdoctoral Fellow	Scientist at Lonza
Charlotte Zammit (2020-current)	Senior Scientist	
Qian Shao (2020-current)	Res. Assistant Professor	

Helen Bui (2020-2022)	Undergraduate Researcher	Student at USC Dental School
Yangzhi (Robby) Wang (2020-2022)	Undergraduate Researcher	PhD program at Tri-I program
Brian So (2019-2022)	Undergraduate Researcher	PhD program at Cornell University
Michelle Tang (2019-2022)	Undergraduate Researcher	PhD program at Stanford University
Jennifer Co (2019-2021)	Undergraduate Researcher	PhD program at Stanford University
Erika Zhang (2019-2022)	Undergraduate Researcher	PhD program at MIT
Lydia Zhang (2019-2023)	Graduate Researcher	Scientist at Arcus Biosciences
Flor (Alicia) Gowans (2019-2023)	Graduate Researcher	Scientist at Genentech
Nathaniel Henning (2019-2022)	Graduate Researcher	Scientist at Gilead
Bridget Belcher (2019-2023)	Graduate Researcher	Technical Adviser at Desmarais LLP
Deirdre Willgohs (2018-2018)	Research Intern	Student at Northwestern University
Benjamin Fontaine (2018-2021)	Postdoctoral Fellow	Scientist at LifeMine Therapeutics
Lydia Boike (2018-2022)	Graduate Researcher	COO at Elate
Chad Altobelli (2018-2019)	Undergraduate Researcher	PhD program at UCSF
Angela Xiong (2018-2019)	Undergraduate Researcher	PhD program at Boston College
Felix Majewski (2018-2020)	Undergraduate Researcher	PhD program at Stanford University
Ross White (2018-2019)	Undergraduate Researcher	Research Specialist at Scribe Therapeutics
Sarah Buzsaki (2018-2020)	Undergraduate Researcher	PhD program at Rice University
May Fung (2018-2020)	Postdoctoral Fellow	Scientist at Hong Kong Jockey Club
Sasha Demeulenaere (2018-2018)	Undergraduate Researcher	MD/PhD student at Loyola Medicine
Kenneth Kim (2017-2021)	Undergraduate Researcher	
Christine Thatcher (2017-2018)	Undergraduate Researcher	Scientist at Lawrence Livermore National Laboratory
Yosuke Isobe (2018-2020)	Postdoctoral Fellow	Deputy Team Leader at RIKEN
Clive Yik Sham Chung (2017-2020)	Postdoctoral Fellow	Assistant Professor at Hong Kong University
Katherine Near (2017-2019)	Postdoctoral Fellow	Scientist at Nurix
Alexander Cioffi (2017-2019)	Postdoctoral Fellow	Scientist at Frontier Medicines
Lisha Ou (2017-2019)	Undergraduate Researcher	PhD program at Stanford University
Linda Waldherr (2017-2017)	Visiting Grad Student	Postdoc, Medical Univ of Graz
Raymond Ho (2017-2018)	Undergraduate Researcher	MD/PhD program at Baylor
Sage Geher (2017-2017)	Undergraduate Researcher	Research Assistant, University of Utah
Mai Luo (2016-2020)	Postdoctoral Fellow	Assistant Professor at China Agricultural University
Tamara Tomin (2016-2017)	Visiting Grad Student	Senior Scientist at Technische Universitat Wien
Alex Renn (2016-2017)	Undergraduate Researcher	
Jordan Kleinman (2016-2019)	Research Associate	PhD program at UCSF
Ashley Ives (2016-2017)	Undergraduate Researcher	PhD program at Northwestern University
Jessica Spradlin (2016-2020)	Graduate Researcher	Scientist at Revolution Medicines
Carl Ward (2016-2020)	Graduate Researcher	F99/K00 Postdoc at UCSF
Allison Roberts (2015-2018)	Graduate Researcher	Senior Scientist at Frontier Medicines
Amanda Wiggenhorn (2016-2019)	Research Associate	PhD program at Stanford University
Joseph Hendricks (2016-2017)	Undergraduate Researcher	PhD program at UC Berkeley
Anna Flury (2016-2016)	Lab Assistant	
Haley Lehtola (2016-2018)	Undergraduate Researcher	Medical student at Western University of Health Sciences
Yana Petri (2016-2019)	Research Associate	PhD program at MIT
Justin Wang (2016-2017)	Undergraduate Researcher	PhD program at Scripps Research
Ivan Atencio (2016-2017)	Undergraduate Researcher	Process Engineer at EXP
Andrew Hong (2016-2016)	Undergraduate Researcher	MD/PhD program at University of Rochester

Catherine Cascavita (2015-2016)	Lab Manager	Associate at Genentech
Elizabeth Grossman (2014-2019)	Graduate Researcher	Principal Scientist at Novartis
Michelle Luu (2015-2017)	Undergraduate Researcher	Emergency Room Scribe at Vituity
Deepika Raghavan (2015-2016)	Undergraduate Researcher	Medical Student at University of Iowa
Peter Yan (2015-2017)	Undergraduate Researcher	Medical Student at UCLA
Kimberly Anderson (2015-2018)	Graduate Researcher	Scientist at Frontier Medicines
Melanie Hubbuck (2015-2017)	Graduate Researcher	PhD student at Washington University
Megan Duckering (2015-2016)	Undergraduate Researcher	Senior Life Sciences Consultant at Guidehouse
Angela Yang (2015-2015)	Undergraduate Researcher	Research Assistant at Stanford University
Charles Berdan (2014-2019)	Graduate Researcher	Associate Consultant with McKinsey and Company
Wan-Min Ku (2014-2017)	Undergraduate Researcher	Manager, Solution Delivery at Pfizer
Derek Barbas (2014-2015)	Undergraduate Researcher	
Leslie Bateman (2014-2016)	Postdoctoral Fellow	Senior Scientist at Neomorph
Breanna Ford (2014-2019)	Graduate Researcher	Scientist at BASF
Wallace Lowe (2014-2015)	Undergraduate Researcher	Lab assistant at Cottage Health
Tucker Huffman (2014-2017)	Undergraduate Researcher	Scientist at Ferring Pharmaceuticals
Olivia Dibenedetto (2014-2014)	Undergraduate Researcher	Account Manager at Quantcast
Jeffrey Coleman (2014-2014)	Undergraduate Researcher	Scientist at NeoGenomics Labs
Lara Bideyan (2014-2015)	Undergraduate Researcher	Postdoc at UT Southwestern
Esha Dalvie (2013-2016)	Undergraduate Researcher	Postdoc at MIT
Daniel Li (2013-2015)	Undergraduate Researcher	Postbac at NIH
Jessica Counihan (2013-2018)	Graduate Researcher	Consultant for ClearView Healthcare Partners
Sharon Zhong (2013-2015)	Undergraduate Researcher	
David Miyamoto (2013-2015)	Undergraduate Researcher	PhD program at Harvard University
Karl Fisher (2013-2014)	Associate Specialist	Director of Chemistry at Lygos
Lauryn Chan (2013-2014)	Undergraduate Researcher	Food Technologist at Beyond Meat
Lucky Ding (2013-2016)	Undergraduate Researcher	Medical Student at UCSF
Nivedita Keshav (2013-2014)	Undergraduate Researcher	Medical Student at UCLA
Ann Heslin (2013-2015)	Undergraduate Researcher	Associate Product Manager at Veeva
Chynna Tang (2013-2014)	Undergraduate Researcher	Graduate student in UC Berkeley Optometry Program
Yoav Azaria (2012-2014)	Undergraduate Researcher	Research Assistant at Genentech
Devon Hunerdosse (2012-2015)	Graduate Researcher	Senior Research Biologist at 3M
Lindsay Roberts (2012-2017)	Graduate Researcher	Senior Scientist, Nuredis Inc.
Ramandeep Dhillon (2012-2015)	Administrative and Lab Asst.	Medical Doctor
Alice Shieh (2012-2013)	Undergraduate Researcher	Undergraduate at Duke University
Tara Narasimhalu (2012-2014)	Undergraduate Researcher	Medical Resident at UCLA
Rebecca Kohnz (2012-2016)	Postdoctoral Fellow	Senior Scientist at Merck
Patrick Morris (2012-2014)	Postdoctoral Fellow	Staff Scientist at NCI/NIH
Melinda Mulvihill (2012-2014)	Postdoctoral Fellow	Senior Scientist at Genentech
Alyssa Cozzo (2012-2013)	Undergraduate Researcher	Researcher in Mina Bissell Lab, LBNL
Daniel Medina-Cleghorn (2011-2015)	Graduate Researcher	Scientist at Nurix
Jay Andrew Cosme Barcelon (2011-2012)	Undergraduate Researcher	Strategic Market Access & Intelligence Analyst at XCenda
McKenna Green (2012-2014)	Undergraduate Researcher	Resident Physician at Detroit Medical Center
Daniel I Benjamin (2011-2015)	Graduate Researcher	Postdoc at Stanford in Tom Rando Lab
Sharon M Louie (2011-2017)	Graduate Researcher	Scientist at CohBar
Anayo Ohiri (2011-2013)	Undergraduate Researcher	Graduate Student at SF State
Jae Wong Chang (2009-2011)	Graduate Researcher Undergraduate Researcher	Postdoctoral Fellow at U. Chicago

Anna M. Ward (2004-2008, 2010) Roger Issa (2004-2008)	Undergraduate Researcher	Anesthesiology Resident at Harvard Medical School Principal Compliance Manager at Genentech